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ABSTRACT 
Peripheral neuropathy (PN) is a common neurological complication occurring in the 
asymptomatic and symptomatic stages of human immune deficiency virus (HIV) 
infection. The pain and other symptoms caused by PN can impair functional ability and 
limit physical activity that could affect quality of life (QoL). Additionally, studies done 
on quality of life of people living with HIV/AIDS have shown that, HIV-related 
neurological syndromes, including PN, significantly reduce QoL. The aim of this study 
was to determine the prevalence of peripheral neuropathy amongst and the quality of life 
of adults living with HIV/AIDS attending the out-patient clinic at Rutongo Hospital in 
Rulindo District in Rwanda. The contributing factors for QoL in people living with 
HIV/AIDS (PLWHs) were also highlighted. A cross-sectional descriptive design using a 
quantitative research method was used. A time constrained sample of 185 of adult 
PLWHs attending out-patient clinic at Rutongo hospital was recruited. The Subjective 
Peripheral Neuropathy Screen (SPNS) was used to screen for the presence of peripheral 
neuropathy and the World Health Organization Quality of Life, short form (WHOQOL 
BREF) to assess quality of life. The Statistical Package for the Social Sciences (SPSS) 
was used to analyse the data. Chi-square Tests were used to demonstrate association 
between demographic characteristics and severity of peripheral neuropathy. Permission 
was sought from relevant committees at University of Western Cape and relevant 
authorities from Rwanda. Written consent was sought from the participants and they were 
assured of respect, confidentiality and anonymity. Participation in the study was 
voluntary and participants were free to withdraw from the study at any time if they so 
wished. One hundred and eighty five adult PLWHs attending out-patients clinic at 
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Rutongo Hospital received and completed the SPNS. The study indicated that 75 (40.5%) 
of respondents experienced peripheral neuropathy in varying grades; 44 (58.7 %) were in 
grade 1 whereas 10 (13.3 %) were in grade 2 and 21 (28 %) in grade 3.  In the present 
study, PLWHs had quality of life scores in the physical health, psychological, social 
relationship and environmental domains that fell in intermediate level (between 10 and 
14.9 with psychological health domain (14.81) close to the high level (between 15 and 
20) and participants scored lower in the physical (12.72) and environmental (12.57) 
domains. Additionally, this study found that education significantly affected the physical 
health, psychological, social and environment domains; Age significantly affected 
psychological domain (P=0.028). Lower scores were seen among subjects who were 
older than 60 years compared to those who were less than 30 years old, while gender, 
marital status and time elapsed since HIV diagnosis significantly affected social domain. 
The results of the indicated that a percentage of PLWHs attending the out-patient clinics 
at Rutongo Hospital in Rwanda had peripheral neuropathy. Various domains of quality of 
life were also affected in some of the participants. The findings suggest that the 
assessment of both peripheral neuropathy and quality of life be included in the 
intervention programmes designed for people living with HIV/Aids. 
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CHAPTER ONE 
INTRODUCTION 
1.1 INTRODUCTION TO THE CHAPTER 
This chapter covers the background information on peripheral neuropathy and quality of 
life of adults living with HIV/AIDS worldwide including the situation in Rwanda. The 
statement of the problem, the research questions, the aim, the objectives, and the 
significance of study are also described. This chapter ends with the definitions of terms 
used as well as the outlines of chapters of this thesis.  
 
1.2 BACKGROUND 
Globally, the estimated number of persons infected with the human immune deficiency 
virus (HIV) is 33.2 million people; of these 22.5 million people are living in Sub-Saharan 
Africa. This 22.5 million constitutes more than two thirds of all people worldwide 
(UNAIDS/WHO, 2007). In addition, unlike other regions the majority of people living 
with HIV in Sub-Saharan Africa (61%) are women. In Rwanda the number of adults 
living with HIV/AIDS was estimated at 150,000 out of 9,609,000 of the general 
population of which 49,000 were receiving antiretroviral therapy (UNAIDS, 2007). 
People living with HIV/AIDS (PLWHs) are likely to experience a steady decline in 
function, as their immune system could become increasingly compromised in the absence 
of antiretroviral therapy (Hughes, Jelsma, Maclean, Darder & Tinise, 2004). Coping with 
HIV/AIDS as a chronic disease presents major medical, psychological and psychosocial 
challenges (Vetter & Donnelly, 2006). Many PLWHs find it challenging to perform 
activities of daily living, participate in moderate to vigorous physical activities, or have 
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sufficient energy or vitality to engage in an active social life while managing HIV/AIDS 
(Vosvick et al., 2003). Moreover, in earlier studies, involvement of the central or 
peripheral nervous system was found to occur across the spectrum of HIV disease 
(Swanson, Zeller & Paice, 1998; Schifitto et al., 2002) and is often associated with 
antiretroviral therapy (Moore, Wong, Keruly & McArthur, 2000). Neurological disorders 
related to HIV often result in reduced quality of life and shortened survival, especially in 
people with more advanced HIV disease (Lichtenstein et al., 2005).   
 
Peripheral neuropathy (PN) is a common neurological complication occurring in the 
asymptomatic and symptomatic stages of HIV infection (Zanetti, Manzano & Gabbai, 
2004). The same authors, in their study conducted in Brasil revealed that 34 of 49 
(69.4%) of the PLWHs having PN; while Parry et al. (1997) found 44% in Zimbabwe. 
With regards to peripheral neuropathy in people living with HIV/AIDS limited 
information is available in Africa, particularly in Rwanda. 
 
 Peripheral Neuropathy can be among the most painful and debilitating of the many 
symptoms associated with HIV/AIDS and its treatment (Ferrari et al., 2006). People 
living with HIV/AIDS may experience a variety of different types of peripheral 
neuropathy (Nicholas et al., 2007). The most common syndrome is distal sensory 
polyneuropathy (DSPN) which occurs mainly in individuals with advanced 
immunosuppression and may occur because of the dideoxy-nucleoside reverse 
transcriptase inhibitors (NRTI) class of antiretroviral therapy (ART)(Lichtenstein et al., 
2005). Other types of PN seen in people with HIV/AIDS include inflammatory 
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demyelinating polyneuropathy; autonomic neuropathy, polyradiculopathy, and 
mononeuropathy multiplex (Wulf, Wang & Simpson, 2000). In people with HIV/AIDS, 
PN most often affects the feet and later the hands, causing numbness, tingling, and/or 
pain (Delakas, 2001). Pain, parasthesias and numbness caused by peripheral neuropathy 
can impair functional ability and limit physical activity, affecting Quality of life (QoL) in 
HIV-positive patients (Swanson et al., 1998). Diagnosis and treatment of PN in the highly 
active antiretroviral therapy (HAART) era represent a challenge because of the overlap of 
clinical symptoms, complexity of treatment choices, and a possible abnormal presentation 
of symptoms of PN during immune reconstitution (Manji & Miller, 2004). Earlier, PN 
has been found to be the most frequent neurological complication in HIV-infected 
individuals where pain was the most common symptom that could significantly impair 
QoL (Verma, Estanislao & Simpson, 2005). 
 
Quality of life (QoL) is defined by the World Health Organisation Quality of Life 
(WHOQOL) Group (1995) as an individuals’ perception of their health in the context of 
the culture and value system in which they live and in relation to their goals, 
expectations, standards and concerns. Quality of life is becoming an important issue for 
the growing numbers of individuals including these living with HIV/AIDS who need to 
adapt to severe and chronic disablement (Casado, 2005). The quality of life of people 
living with HIV/AIDS in Sub-Saharan Africa is a complex constellation of disease, 
stigma, discrimination, and lack of treatment combined with family life, work, and social 
activities (Phaladze et al., 2005). Therefore, QoL measures are increasingly being 
recognised as important when comparing the efficacy of AIDS therapies (Casado, 2005), 
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assessing the impact of HIV/AIDS on peoples’ lives (Wig et al., 2006), and determining 
the impact on quality of life in HIV/AIDS patients for estimating the burden of the 
disease (Sowell et al., 1997). Moreover, QoL in HIV-infected patients is a concept that 
has received increased attention in the literature, as it is recognized that HIV illness can 
impact all aspects of patients’ lives (Molassiotis, Callaghan, Twinn & Lam, 2001).  
 
Studies on HIV patients and quality of life have shown that, compared with patients with 
various other chronic conditions; patients with symptomatic HIV scored their Health-
Related Quality of Life (HRQoL) as poor, while patients with asymptomatic HIV scored 
it better (Globe, Hays, & Cunningham, 1999; Eriksson, Nordstrom, Berglund, & 
Andstrom, 2000). Furthermore, Pandya, Krentz, and Power (2005) found that HIV-
related neurological syndromes, including neuropathy, significantly reduce quality of life. 
Fortunately, there are medical treatments and other measures people with HIV/AIDS can 
take to ameliorate neuropathy symptoms and improve their quality of life. Griswold, 
Evans, Spielman and Fishman (2005) examined coping strategies of HIV patients with 
peripheral neuropathy and found that these strategies may differ according to age, gender 
and ethnic background of those living with HIV. Nicholas et al. (2007) stated that 
pharmacologic approaches, complementary therapies, and self-care behaviors may 
improve quality of life and limit symptoms of distal symmetric peripheral neuropathy. 
 
In Rwanda, HIV/AIDS causes extreme hardship in an already impoverished population. 
USAID report states that only 28 percent of households with a PLWH are able to pay for 
basic care, causing families to borrow money, and sell assets (Uwimana, 2005). In 
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addition, in Rwanda, the gross domestic product (GDP) per capita is $ 250 (National 
Institute of Rwanda (NISR), 2007), making Rwanda one of the poorest countries in the 
world. With a current human resources crisis and a desperate need for qualified health 
professionals, addressing the HIV epidemic has been a difficult challenge. In summary 
report on Rwanda Human Resources Assessment for HIV/AIDS scale-up have shown 
that there was only one doctor for over 50,000 people, and one nurse for every 3,900 
people (Furth, Gass, & Kagubare, 2006). This problem is much worse in rural areas 
(Ministry of Health (MOH). A large number of HIV/AIDS patients are poor and live in 
rural areas where there are limited health facilities; therefore they do not have access to 
counseling and testing services (GoR & William John Foundation, 2003). A study 
conducted in Rwanda indicated that PLWHs face many problems as a result of the 
illness. These include neurological, psychosocial complications and financial difficulties 
(Uwimana, 2005). In addressing the problem of the HIV/AIDS, the strategy of the 
government of Rwanda places particular emphasis on prevention, while at the same time 
providing prophylaxis and treatment for opportunistic infections and antiretroviral 
therapy to all people living with HIV/AIDS irrespective of their social status (Ministry of 
Health, 2005).  
 
1.3 STATEMENT OF THE PROBLEM 
As people living with HIV/AIDS (PLWHs) are living longer, they are beginning to have 
more chronic health problems (Gale, 2003). The incidence of neurologic disease and 
central nervous system infections associated with HIV has declined with the advent of 
HAART (Philips, Skelton, & Hand, 2004). Peripheral neuropathy (PN) is one condition 
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associated with functional limitations and affecting quality of life (QoL) of patients. To 
date, there have been many studies on peripheral neuropathy and HIV disease (Figg, 
1991; Parry et al., 1999; Zanetti et al., 2004). However, little have been done in Africa 
and none in Rwanda. There is therefore a need to determine the prevalence of peripheral 
neuropathy and the quality of life of adults living with HIV/AIDS. 
 
1.4 RESEARCH QUESTIONS 
1. What is the prevalence of peripheral neuropathy in adults living with HIV/AIDS 
attending the out-patient clinic at Rutongo Hospital in Rulindo District in Rwanda? 
2. What is the quality of life of adults living with HIV/AIDS attending the out-patient 
clinic at Rutongo Hospital in Rulindo District in Rwanda?  
 
1.5 THE AIM OF THE STUDY 
The aim of this study is to determine the prevalence of peripheral neuropathy amongst 
and the quality of life of adults living with HIV/AIDS attending the out-patient clinic at 
Rutongo Hospital in Rulindo District in Rwanda?  
 
1.6 SPECIFIC OBJECTIVES 
1. To determine the prevalence of peripheral neuropathy in adults living with HIV/AIDS 
attending the out-patient clinic at Rutongo Hospital in Rulindo District in Rwanda. 
2. To assess the quality of life of adults living with HIV/AIDS attending the out-patient 
clinic at Rutongo Hospital in Rulindo District in Rwanda. 
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2.1. To determine physical health and Level of independency of adults living with 
HIV/AIDS attending the out-patient clinic at Rutongo Hospital in Rulindo District in 
Rwanda. 
2.2. To determine psychological well being of adults living with HIV/AIDS attending the 
out-patient clinic at Rutongo Hospital in Rulindo District in Rwanda. 
2.3. To determine the social relationship of adults living with HIV/AIDS attending the 
out-patient clinic at Rutongo Hospital in Rulindo District in Rwanda. 
2.4. To determine the environment of adults living with HIV/AIDS attending the out-
patient clinic at Rutongo Hospital in Rulindo District in Rwanda. 
 
1.8 DEFINITION OF TERMS 
Quality of life: is defined by the World Health Organisation Quality of life (WHOQOL) 
Group (1995) as individuals’ perception of their position in the context of the culture and 
value system in which they live and in relation to their goals, expectations, standards and 
concerns. 
 
Peripheral neuropathy: Condition characterized by sensory loss, pain, muscle 
weakness, and wasting of muscle in the hands or legs and feet. It may start with burning 
or tingling sensations or numbness in the toes and fingers. In severe cases, paralysis may 
result. Peripheral neuropathy may arise from an HIV-related condition or be the side 
effect of certain drugs, some of the nucleoside analogs in particular (ATIS, 2002). 
 
Adult: Any person who has reached the age of eighteen (18) years and above. 
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PLWHs: A general term referring to all people infected with HIV, whether or not they 
show the infection symptoms. 
 
Antiretrovirals/Antiretroviral Treatment/Antiretroviral Therapy (ARVs/ART): The 
medication for people living with HIV/AIDS that can work to inhibit the weakening of 
and sometimes even strengthen the immune system, protecting patients from developing 
opportunistic infections and allowing for increased life expectancy. There are four 
categories of antiretrovirals: 1) nucleoside reverse transcriptase inhibitors 2) non-
nucleoside reverses transcription inhibitors, 3) protease inhibitors, and 4) fusion or entry 
inhibitors. Combination therapies, like Highly Active Antiretroviral Therapy (HAART), 
reduce the development of drug resistance. Specific drugs may not be effective in 
everyone and side-effects will vary by person (Fan, Conner, & Villareal, 2004). 
 
1.8 OUTLINE OF CHAPTERS 
Chapter one covers the background information on peripheral neuropathy and quality of 
life of adults living with HIV/AIDS worldwide including the situation in Rwanda. The 
statement of the problem, the research questions, the aim, the objectives, and the 
significance of study are also described. This chapter ends with the definitions of terms 
used in the study. 
 
Chapter two presents a review of the literature concerning peripheral neuropathy and 
quality of life of people living with HIV/AIDS. This chapter provides insight into the 
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impact of HIV/AIDS on the quality of life. The relationship between peripheral 
neuropathy and quality of life are also highlighted. Finally, the current therapies of 
HIV/AIDS related peripheral neuropathy are presented. 
 
Chapter three outlines the methods used in the study. It explains the rationale for the 
study design chosen and describes the research setting. The population, the sampling 
method, data collection and analysis are described. Finally, the ethical considerations 
regarding the study are described. 
 
Chapter four describes the results of the data from this study.  
 
Chapter five summarises and discusses the major findings relating to the objectives 
within the study with a comparison to previous research in the area. The limitations of the 
study are also highlighted. 
 
Chapter six summarises the important points of the current study. Recommendations 
related to the findings are also proposed. 
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CHAPTER TWO 
REVIEW OF LITERATURE 
2.1 INTRODUCTION 
This chapter reviews literature related to the causes, prevalence, symptoms, and 
prognosis of peripheral neuropathy among adults living with HIV/AIDS, as the majority 
of those affected are adults. Literature on the impact of HIV/AIDS on the quality of life 
as well as the relationship between peripheral neuropathy and quality of life is also 
reviewed. 
 
Data for this review were based on information obtained from data bases such as 
Academic Search Premier, Cinahl, PubMed (Medline), Science direct, Eric and manual 
searches of the English literature from early 1995 through 2008. Key words or text words 
included as search terms for the review was: Quality of life AND assessment OR 
measurement OR examination; Quality of life AND HIV/AIDS; HIV/AIDS OR infection 
HIV; Peripheral neuropathy; Distal symmetrical polyneuropathy. A manual search was 
performed for the references cited in relevant studies.  
 
2.2 HIV/AIDS  
2.2.1 Description of HIV 
The human immunodeficiency virus (HIV) is a retrovirus which causes chronic, 
progressive, immunological dysfunction (Chin, 2007). Infection with HIV is 
characterized by a long period with no or minor symptoms, but the virus causes declining 
levels of T-helper (CD4-positive) lymphocytes. Low levels of CD4-positive lymphocytes 
are associated with increased risk of the acquired immunodeficiency syndrome (AIDS), a 
 
 
 
 
 11
condition in humans in which the immune system begins to fail, leading to life-
threatening opportunistic infections. A person may live with HIV for up to 10 years 
before developing AIDS. AIDS eventually leads to death due to the development of 
opportunistic infection such as viral, bacterial and fungal infections (Fan et al., 2004). 
HIV may be transmitted through blood or, most often, through sexual fluids. 
 
2.2.2 Prevalence of HIV/AIDS 
This section includes the general overview of HIV/AIDS worldwide, in Sub-Saharan 
Africa including the situation in Rwanda on impacts of HIV/AIDS on health system and 
strides in antiretroviral therapy. 
 
Globally, the estimated number of persons living with human immune deficiency virus 
(HIV) in 2007 was 33.2 million [30.6–36.1 million]. This indicated a reduction of 16% 
compared with the estimate published in 2006 (39.5 million [34.7–47.1 million]) 
(UNAIDS/WHO, 2006). The HIV and acquired immunodeficiency diseases (AIDS) 
pandemic has become a major challenge to health, development and humanity 
(UNAIDS/WHO, 2006). Although, HIV and AIDS are found in all parts of the world, 
some areas are more afflicted than others. HIV/AID affects many different populations, 
and occurs in every country in the world; however, a disproportionate number of these 
affected live in the poorer countries of the world. In addition, around 80% of the global 
populations live in developing countries, but these countries are home to 95% of those 
with HIV/AIDS. 
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According to the UNAIDS (2007) report, the sub-Saharan Africa region is more heavily 
affected by HIV and AIDS than any other region of the world. More than two thirds 
(68%) of all people who are HIV-positive live in this region where more than three 
quarters (76%) of all AIDS deaths in 2007 occurred. Unlike other regions, the majority of 
people living with HIV in sub-Saharan Africa (61%) are women. In four sub-Saharan 
African countries, national adult prevalence has raised higher than was once thought 
possible, exceeding 30% in Botswana (38.8%), Lesotho (31%), Swaziland (33.4%) and 
Zimbabwe (33.7%) (UNAIDS, 2002). In addition, UNAIDS report states that 24.5 
million people were living with HIV at the end of 2005 and approximately 2.7 million 
additional people were infected with HIV during that year.  In 2004, the AIDS epidemic 
in Africa has claimed the lives of an estimated 2 million people in this region. More than 
twelve million children have been orphaned by AIDS. They further reported that both 
HIV prevalence rates and the numbers of people dying from AIDS vary greatly between 
African countries. For example, in Somalia and Senegal the HIV prevalence is under 1% 
of the adult population, whereas in South Africa and Zambia around 15-20% of adults are 
infected with HIV.  
 
In spite of improved access to antiretroviral treatment and care in many parts of the 
world, an estimated 3.1 million people lost their lives to the disease in 2005 (UNAIDS, 
2005). Moreover, the government of Rwanda is committed to providing its population 
with required HIV/AIDS health services. To meet the urgent needs of Rwandans for 
HIV/AIDS prevention, care and treatment, the Ministry of Health aims to scale-up 
HIV/AIDS service provision to treat 100,000 antiretroviral therapy (ART) clients by 
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2007 (TRAC, 2004). However, Rwanda has made remarkable strides in antiretroviral 
therapy and care of opportunistic infections. As of July 2004, 23 sites were offering 
HIV/AIDS care and treatment services and as of the end of September 2004, a total of 
6,230 clients had started ARVs. Although, Nicholas et al. (2007) stated that with 
antiretroviral therapy, PLWHs are expected to develop peripheral neuropathy, the most 
common neurological complication in HIV.  
 
2.3 PERIPHERAL NEUROPATHY IN HIV/AIDS 
2.3.1 Definition of peripheral neuropathy  
Peripheral neuropathy (PN) is damage to the peripheral nerves and is characterized as an 
injury, inflammation, or degeneration of the peripheral nerves fibers (Pascuzzi, 2003). 
The peripheral nerves represent the nerves outside the brain and spinal cord and consist 
of motor, sensory, and autonomic nerve fibers. Depending on the fiber classes affected, 
neuropathies are subdivided into motor, motor and sensory, and pure sensory forms. In 
addition, autonomic disturbances may be present leading to the additional classification 
into autonomic or autonomic and sensory neuropathies. Sensory neuropathies affect the 
sensory nerves, which are the nerves responsible for sensation throughout the body. Most 
commonly sensory neuropathies affect the feet and legs, and less frequently the hands 
and arms. The diagnosis of sensory neuropathy requires a history compatible with 
predominantly sensory dysfunction and a physical examination notable for abnormal 
sensory findings at least in the feet, with reduced or absent ankle jerks (Armstrong, 
2000).  
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2.3.2 Peripheral neuropathy and HIV/AIDS 
This section focuses on peripheral neuropathy in HIV/AIDS and discusses the causes, 
prevalence and incidence, symptoms, and prognosis of this disorder. Distal sensory 
polyneuropathy (DSPN) is described in more detail. 
 
2.3.2.1 Causes of peripheral neuropathy 
Peripheral neuropathy is one of the most frequent neurologic disorders associated with 
HIV infection (Wulff et al., 2000; Cherry, Wesselingh, Lal & McArthur, 2005; 
Lichtenstein et al., 2005; Dorsey & Morton, 2006; Ferrari et al., 2006). Its symptoms 
cause substantial morbidity and discomfort to patients with AIDS. PN can result from the 
direct infection of neurons with human immunodeficiency virus (HIV), opportunistic 
infection of neurons because of generalized immunosuppression, and from highly active 
antiretroviral therapy (HAART) (Hurst, 1999; Moyle & Sadler, 1998). As neuropathy 
results from HAART treatment as well as HIV infection, it does not improve dramatically 
with HAART-related reductions in HIV viral load (Simpson & Tigliati, 1995).  A 30%–
35% prevalence of peripheral neuropathy has been documented in PLWHs, but autopsy 
based studies have found it in nearly 100% of patients who died of AIDS. HIV-associated 
PN is known to exist in at least six patterns such with distal sensory polyneuropathy 
(DSPN) as the most frequently occurring (Nicholas et al., 2007). Other types of 
peripheral neuropathy include inflammatory demyelinating polyneuropathy, progressive 
polyradiculopathy, mononeuropathy multiplex, autonomic neuropathy, and diffuse 
infiltrative lymphocytosis syndrome (Wulff et al., 2000). The DSPN associated with HIV 
occurs in the later stages of HIV disease, usually after the patient has had other AIDS 
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defining illnesses. Symptoms of HIV‐associated sensory neuropathies are almost 
identical to those of other sensory neuropathies. Therefore, because DSPN is the most 
common type of HIV/AIDS-related neuropathy, “peripheral neuropathy” and “PN” will 
be used to refer to DSPN throughout the rest of this review of literature unless otherwise 
stated.  
 
Distal sensory polyneuropathy (DSPN) occurs mainly in individuals with advanced 
immunosuppression and may occur because of the dideoxy-nucleoside reverse 
transcriptase inhibitors (NRTI) class of antiretroviral therapy (ART) (Lichtenstein et al., 
2005). Delakas (2001) and Simpson & Cikurel (2006) suggest that the symptoms of 
nucleoside reverse transcriptase inhibitor (NRTI)-related DSPN are essentially identical 
to the syndrome of DSPN that is associated with HIV disease, thus potentially 
confounding the diagnosis and treatment of neuropathy. They further suggest that 
distinguishing HIV-associated neuropathy from NRTI-related neuropathy may be 
accomplished by examining the temporal association of symptoms with initiation of 
NRTI treatment, clinical or electrophysiologic improvement after dose reduction or drug 
discontinuation, and the “coasting” effect, in which symptoms increase for 2 to 4 weeks 
after drug discontinuation, followed by clinical improvement. Dieterich (2003) suggests 
that NRTI-related neuropathy is more likely than HIV-induced neuropathy to be painful, 
have an abrupt onset, and progress rapidly.  
 
Pardo, McArthur and Griffin (2001) suggest that the pathophysiology of DSPN and 
antiretroviral toxic neuropathies (ATN) includes three specific mechanisms: “dying 
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back” axonal degeneration of long axons in distal regions, loss of unmyelinated fibers, 
and a variable degree of macrophage infiltration in peripheral nerves and dorsal root 
ganglia. HIV-associated neuropathies differ from ATN neuropathies. For ATN-associated 
neuropathies, interference with DNA synthesis and mitochondrial abnormalities produced 
by nucleoside ART were linked to the symptom manifestation (Simpson & Cikurel, 
2006).  
 
2.3.2.2 Prevalence and incidence of peripheral neuropathy 
It is reported that 39%-70% of all people living with HIV/AIDS developed neurological 
disorders (Janssen, 1997). Pre-HAART studies have shown that advanced 
immunosuppression, as reflected by reduced CD4+ cell counts and increased HIV viral 
load increases the risk and severity of neuropathy (Lichtenstein et al., 2005). 
Additionally, highly active antiretroviral therapy (HAART) has led to an increasing pool 
of long-term survivors with HIV disease and this may in turn lead to an increase in the 
prevalence of neurologic conditions, particularly as some individuals experience 
virologic failure of their ARV therapy.  
 
Peripheral neuropathy has not declined in frequency, even in the HAART era, 
particularly in recipients of d-drug ARV regimens. This may, in part, explain a 
diminished impact of HAART on the incidence of PN. According to Sacktor (2002) the 
increased life expectancy of HIV-infected individuals through highly active antiretroviral 
therapy (HAART) increases the prevalence of peripheral neuropathies. The increase in 
DSPN has occurred in relation to the increased use of potentially neurotoxic antiretroviral 
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drugs (Schifitto et al., 2005; Simpson et al., 2003), as well as advanced HIV disease. As 
DSPN has emerged as a major side-effect of antiretroviral therapy, persons with any 
stage of HIV may be affected. In an earlier study, DSPN was found to occur across the 
spectrum of HIV disease and its incidence was increasing due to prolonged survival rates 
and the development of HAART (Dorsey & Morton, 2006). Contrary, HAART lessens 
disease progression, improves immunity, and widens the ratio of therapeutic to toxic 
effects of individual antiretroviral drugs, resulting in a significantly lower risk of 
developing DSPN (Schifitto et al., 2005) and since HAART was introduced, the 
incidence of DSPN has decreased. However, recent reports suggest that HAART may 
have a beneficial effect on PN function among patients with early disease (Simpson et al., 
2006). Therefore, an important clinical question to be answered is how to predict which 
patients are at highest risk for the development of PN while being treated with d-drug 
regimens. 
 
Different prevalence rates of peripheral neuropathy in people living with HIV/AIDS have 
been reported in the literature .This may be due to different methodology, defining 
criteria, and patient populations. The reported frequency of HIV peripheral neuropathy 
ranges from 10 to 35% (Snider et al., 1983; Cornblath and McArthur, 1988; So, 
Holtzman, Abrams, & Olney, 1988; McArthur et al., 1989; Schifitto et al., 2002), 
although this varies when the diagnosis is based on only neurological exams (e.g. 10%) 
(Cornblath and McArthur, 1988), or on EMG (e.g. 35%) (So et al., 1988). Importantly, 
the frequency of symptomatic peripheral neuropathy has remained unchanged (e.g. 35%) 
(Schifitto et al., 2002), even after the introduction of antiretroviral medication and 
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HAART, which appears to be due to the neurotoxic effect of these medications. For 
example, ddC has been implicated in the etiology of peripheral neuropathy in HIV-
infected patients (Blum et al., 1996). 
 
DSPN is detected by clinical examination in 30% of infected patients (Swanson et al., 
1998; Zanetti et al., 2004). Neurologic examination reveals depressed or absent ankle 
tendon reflexes in 96% to 100% of cases in PLWHs with predominantly sensory 
neuropathy (Cornblath & McArthur, 1988). In addition, sensations of pain and 
temperature are impaired in the distal portion of the legs in 85% of patients.  In one 
study, DSPN showed a significant decline in prevalence from 42.5% in 1995-1996 to 
34.4% in 1997-1998 (Maschke et al, 2000). In contrast, the prevalence of suspected drug-
induced polyneuropathy increased to 31% compared with 20% in 1995-1996. Moreover, 
after the introduction of HAART, DSPN was not associated with increased HIV-1 load or 
decreased CD4 T-cell count (Morgello, Estanislao & Simpson, 2004). Furthermore, 
DSPN occurs most frequently in advanced HIV infection and is inversely correlated with 
CD4 counts (Simpson & Tigliati, 1995). Tagliati, Grinnel, Godbold, and Simpson (1999) 
reported that the prevalence of HIV-associated neuropathy increases as immune function 
deteriorates. This relationship suggests that a patient presenting with high CD4 counts 
may not be suffering from HIV-associated DSPN alone, but also from neurotoxicity or 
other underlying conditions. The risk of developing DSPN increased during the initial 
period of drug therapy, especially when therapy was started in patients with low CD4 
lymphocyte counts (50-90 cells/L) and higher HIV-1 load (>10,000 copies/mL). The 
authors suggested that disease progression and host factors have a strong independent 
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association with an increased risk of the development of DSPN but also may predispose 
individuals to the neurotoxic effects of antiretroviral medications.  
 
2.3.2.3 Symptoms of peripheral neuropathy 
Individuals with HIV/AIDS experiencing DSPN may present with a number of different 
complaints; the earliest symptoms of peripheral neuropathy are pain, numbness, and 
tingling in the hands and feet in the classic "sock and glove" distribution (Delakas, 2001; 
Simpson & Cikurel, 2006). Verma et al. (2005) in their study on controlling neuropathic 
pain in HIV reported that neuropathic pain constitutes approximately 25% to 50% of all 
pain clinic visits.  Some people describe an altered sensation when picking up objects, as 
if their fingers are "made of plastic", or feelings of their hands and feet falling asleep. The 
patient may complain of their feet throbbing or cramping at night or of stumbling when 
they try to walk. The symptoms are generally symmetric (occur on both sides of the 
body), although they may be more severe on one side. If the neuropathy is severe, 
touching the affected extremity can feel like an open wound is being touched. 
Additionally, many people with early or mild PN do not experience any symptoms and, 
again, the worst symptoms generally occur in people with more advanced 
immunosuppression (lower CD4 cell counts) (Simpson & Cikurel, 2006).  
 
Symptom progression may be very gradual, or may worsen rapidly over a period of days 
or weeks. In most people with HIV/AIDS, altered sensations and pain occur first in the 
toes and soles of the feet; then, as nerve injury progresses, pain and numbness may 
extend to the ankles (Swanson et al., 1998). The same author stated that any tactile 
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stimuli to the affected area such as socks, bed sheets, or shoes can cause discomfort in 
some cases. In late stages of DSPN, the upper extremities may also be affected with 
involvement of the fingers, hands, and wrists respectively. Research reports that when 
asked to describe their symptoms of peripheral neuropathy, the most frequent descriptor 
used is pain, followed by numbness, tingling, burning, and stinging (Nicholas et al., 
2002). Furthermore, Uwimana (2005) found that the numbness and paraesthesia in hands 
and feet were most common symptoms among PLWHs in Rwanda. Other clinical 
features of DSPN include increased vibratory thresholds and reduced pinprick and 
temperature sensation in a stocking and glove distribution. Muscle strength and joint 
position sensation are relatively normal. Symptomatic weakness appears late in the 
disease and is generally restricted to the distal intrinsic foot muscles (Stokes, 2004). 
 
2.3.2.4 Prognosis of peripheral neuropathy 
The diagnosis of peripheral neuropathy can generally be made by a healthcare provider 
who is experienced in the treatment of HIV disease based on a history of the symptoms 
and a comprehensive physical examination which includes testing of the reflexes and 
evaluation of the sense of vibration, touch, pressure, and pain in the extremities (Swanson 
et al., 1998). On neurological exam, abnormalities may exist because of reduced or 
absent ankle reflexes and increased vibratory thresholds (Simpson & Cikurel, 2006). 
Nerve conduction studies can be useful to confirm the diagnosis of DSPN by revealing 
abnormal sensory nerve potential amplitudes and conduction velocity, especially of the 
sural nerve as suggested in the literature (Stokes, 2004). Electromyographic testing may 
be warranted with DSPN however, many have normal nerve conduction. Another 
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diagnostic approach may be to refer for skin biopsy visualization of the epidermal nerve 
fibers (Zanetti et al., 2004). Moreover, in a study done by Phillps et al. (2004), the 
subjective peripheral neuropathy screen (SPNS) was used to examine the pins and needle 
sensations and numbness. According to McArthur (1998), SPNS is a brief, self-report 
tool currently used to screen patients for sensory symptoms indicative of neuropathy in 
most of the primary infection protocols. Additionally, it is used to monitor antiretroviral 
neurotoxicity and to exclude patients with existing neuropathy from entry into clinical 
trials of potentially neurotoxic agents. 
 
The management of peripheral neuropathy is targeted at relieving painful neuropathic 
symptoms and to educate patients regarding prevention of complications. A variety of 
measures can help to relieve the symptoms of PN. It is important to determine whether 
DSPN is related to the HIV disease and not to other causes such as HAART medications, 
nutritional deficiencies, diabetes mellitus, substance abuse, other medications, or medical 
comorbidities and treat accordingly. Treatment for DSPN related to HIV/AIDS may 
incorporate both pharmacologic and nonpharmacologic strategies. In individuals with 
mild symptoms, relief may be reported with lifestyle modifications such as avoiding 
walking long distances, standing for long periods of time, or wearing restrictive shoes 
(Swanson et al., 1998). Other self-care strategies that have been reported to be helpful 
include nutritional supplements, soaking feet in warm water, exercise, rest, elevation of 
extremities, and rubbing the feet with cream (Nicholas et al., 2007).  
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Complementary modalities have also been reported to be helpful for some individuals in 
the management of DSPN as well as for prevention and alleviation of ART side effects 
(Nicholas et al., 2007). Alternative treatments include Yoga, meditation, physical 
modalities (i.e., heat, whirlpool, and massage), traditional Chinese medicine (such as 
acupuncture and tai chi), hypnosis, and creative arts may be beneficial as adjuvant 
therapies and, in some instances, if preferred by patients, as primary pain management 
approaches (Breitbart & Dibiase, 2002). In a study performed to determine the effects of 
5 weeks of individualized acupuncture treatment, delivered in a group setting , on pain 
and symptoms of peripheral neuropathy associated with HIV infection (Phillips et al., 
2004), it was shown that acupuncture significantly reduced present pain, most and least 
pain in the past 24 hours, and total summary pain. In addition, the acupuncture regimen 
reduced pain/ aching/ burning and pins/ needles/ numbness in upper and lower limbs. 
Pharmacologic agents should be incorporated in the management of DSPN if lifestyle 
modifications and complementary modalities do not adequately control pain related to 
DSPN (Nicholas et al., 2007). However, symptomatic treatment with pharmacologic 
agents is often requested by patients, but no specific characteristics of the pain can 
predict which agents will be beneficial. The choice of medication is based on the severity 
of the patients’ symptoms and the side‐effect profile of the medication. Verma et al. 
(2005) suggest that although no standard treatment for DSPN is available, most therapies 
are directed toward relief of symptoms.  
In some patients with mild neuropathic pain, the use of nonsteroidal anti-inflammatory 
agents such as ibuprofen might be successful. Simpson and Cikurel (2006) suggest that it 
is very important to offer appropriate, effective doses of analgesics, which may include 
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NSAIDS, topical medications, narcotics, and adjuvant analgesics. In particular, controlled 
studies of gabapentin and pregabalin have recently shown great benefit in the treatment 
of patients with painful peripheral neuropathies. Similarly, lamotrigine has been reported 
as a well-tolerated and effective treatment for HIV-associated neuropathic pain 
(Backonja, 2002; Simpson et al., 2000). For patients with very severe neuropathic pain, 
the use of opiates and narcotic agents may be necessary. Like the tricyclics, these agents 
must be titrated to the minimum effective dose required for improvement (Auer-
Grumbach, Mauko, Auer-Grumbach, & Pieber, 2006). Furthermore, treatments of DSPN 
have been used to improve neuropathic symptoms and energy levels in individuals living 
with HIV, with many experiencing improved quality of life (Agnoletto, Chiaffarino, 
Nasta, Rossi, & Parazzini, 2003). Thus, effective management of symptoms is important 
for improving QoL. According to Lorenz, Shapiro, Asch, Bozzette and Hays (2001), 
most persons living with chronic illnesses appraise their quality of life (QoL), at least in 
part, according to the symptoms (including treatment side effects) they experience. As 
mentioned above a variety of measures can help to relieve the symptoms of PN. Table 2.1 
summarises the intervention studies in the management of peripheral neuropathy. 
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Table 2.1 Intervention studies in the management of peripheral neuropathy 
 
Authors Design Intervention Sample size Outcome measure Results 
Shlay et al., 
1998 
RCT Standarized 
acupuncture 
regimen (SAR) vs 
control points, 
amitriptyline 
(75 mg/d) vs 
placebo, or both 
for 14 weeks 
250 total patient: 
239 in acupuncture 
comparison 
(125 in the factorial 
option and 114 in 
the SAR option vs 
control points 
option), 
and 136 patients 
were in the 
amitriptyline 
comparison (125 in 
the factorial option 
and 11 in 
amitriptyline option 
vs placebo option). 
Changes in mean 
pain scores at 6 
and 14 weeks, 
using a pain scale 
ranging from 0.0 
(no pain) to 1.75 
(extremely 
intense), recorded 
daily. 
Neither acupuncture nor 
amitriptyline was more 
effective than placebo in 
relieving pain caused by 
HIV-related peripheral 
neuropathy. 
Phillips et 
al., 2004 
Pre and 
post test 
case series 
5 weeks of 
acupuncture 
treatment. 
-10–15 needle 
insertions in 
acupoints for 30–
45 minutes 
Twenty-one (21) 
subjects 
Pain Rating Scale 
and the Subjective 
Peripheral 
Neuropathy 
Screen (SPNS)  
Subjective pain and 
symptoms of peripheral 
neuropathy were reduced 
during the period of 
individual acupuncture 
therapy delivered in a 
group setting. 
McArthur et 
al., 2000 
RCT Subcutaneous 
injections (0.1 
µg/kg rhNGF, or 
0.3 µg/kg rhNGF) 
twice weekly for 18 
weeks.  
270 patients with 
HIV-associated SN 
- self-reported 
neuropathic pain 
intensity (Gracely 
Pain Scale).  
- Global 
improvement in 
neuropathy  
- punch skin 
biopsies for nerve 
fibre densities. 
A positive effect of 
recombinant human nerve 
growth factor on 
neuropathic pain and pin 
sensitivity in HIV-
associated sensory 
neuropathy. rhNGF was 
safe and well tolerated, 
but injection site pain was 
frequent. 
Simpson et 
al., 2000 
RCT Lamotrigine was 
initiated at 25 mg 
per day and slowly 
titrated over 7 
weeks to 300 mg 
per day 
- Total 42 patients 
- 13 drop outs 
- 20 patients 
received placebo 
and 9 received 
lamotrigine 
-change in pain on 
the modified 
Gracely scale  
secondary outcome 
measures  
-Change in 
neurologic 
examination,  
- Use of 
concomitant 
analgesic, 
medications, and 
global pain relief. 
Lamotrigine showed 
promise in the treatment 
of pain associated with 
HIV-related DSP.  
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2.4 QUALITY OF LIFE OF PLWHs 
2.4.1 Quality of life overview 
The definitions and descriptions of quality of life include both objective (income, living 
situations and physical functioning) and subjective (individual’s perception of important 
life domains and satisfaction with those domains) indicators of physical and 
psychological phenomena (Steenburgen & Rogers, 1997).  A more operational definition 
of QoL has acknowledged that it is a complex and multidimensional concept that is 
difficult to define and measure (Casado, 2005). Quality of life is a term that is popularly 
used to convey an overall sense of well being and includes aspects such as happiness and 
satisfaction with life as a whole. However, the World Health Organisation has defined 
quality of life “as individuals’ perception of their position in life in the context of culture 
and value systems in which they live and in relation to their goals, expectations, standards 
and concerns. It is a broad ranging concept incorporating in a complex the person’s 
physical health, psychological state, level of independence, social relationships, personal 
beliefs and their relationship to salient features of the environment” (WHO, 1999).  
 
The quality of life as stated previously is a multidimensional concept and since quality of 
life assessment is essentially subjective it should include the patient’s perspective (Cella 
& Tulsky, 1990). Health-related quality of life is one dimension of quality of life and has 
become increasingly important in recent decades as an outcome in health care (Testa & 
Simonson, 1996), especially when evaluating interventions for patients with chronic 
diseases (Patrick & Eriksson, 1993). Many publications focus on these components of 
quality of life as well as the fact that health-related quality of life is influenced both by 
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disease and treatment but also by personal characteristics such as coping or internal locus 
of control and by living conditions including for example, access to care and financial 
status (Bullinger & Von Mackensen, 2004). Additionally, health-related quality of life in 
clinical settings may be defined as a condition with specific symptoms which are body 
discomfort, social and role functioning, overall perception of health, cognitive status, and 
general well-being (Cleary et al., 1993); while in research, the quality of life instruments 
provide new insights into the nature of disease by assessing how disease impairs or 
impacts the subjective well-being of a person across a whole range of areas (Hakuzimana, 
2005). The consequences of disease and its treatment represent only on group of 
influences on quality of life; though, there are many more aspects including 
demographics, personality, economic status, environment, social relationships, and 
culture.  
 
2.4.2 Quality of life and HIV/AIDS 
Quality of life among HIV-infected individuals has been studied extensively, and prior 
research has attempted to both assess quality of life and determine predictors for good or 
poor quality of life (Mweemba, 2008). Additionally, persons infected with HIV are not 
only concerned with a treatment’s ability to extend life but also with the quality of the life 
they are able to lead (Demmer, 2001). Quality of life for patients living with HIV disease 
has become increasingly important, with the goals of therapy now including improvement 
of quality of life in addition to the reduction of symptoms, suppression of the virus, and 
extension of survival (Molassiotis et al., 2001).  
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People living with human immunodeficiency virus and acquired immunodeficiency 
syndrome (HIV/AIDS) experience numerous symptoms due to the disease, side effects of 
medication and comorbidities. Wachtel et al. (1992) found that patients with HIV/AIDS 
with severe symptoms had lower scores on quality of life, while Kemppainen (2001) 
found that quality of life deteriorated along with an increasing number of symptoms. The 
symptoms often experienced by patients with HIV/AIDS, such as fatigue, diarrhoea, 
insomnia and oral dryness, are often associated with the drug side effects of the drugs. 
Additionally, presence of physical symptoms, especially chronic diarrhea, is associated 
with low quality of life, irrespective of CD4 cell counts (Watson, Samore & Wanke, 
1996). Quality of life in HIV-infected patients is a concept that has received increased 
attention in the literature, as it is recognized that HIV illness can impact all aspects of 
patients’ lives (Lubeck & Fries, 1997). In addition, Yen et al. (2004) stated that quality of 
life levels of HIV/AIDS patients differed according to the method used to measure 
quality of life. In the same study, they found that male outpatients with few current 
HIV/AIDS-infection symptoms had medium quality of life levels according to the 
WHOQOL-BREF. Asymptomatic patients have been found to consistently report higher 
quality of life scores than symptomatic patients and patients with an AIDS diagnosis 
(Burgoyne & Saunders, 2001). Parsons, Braaten, Hall and Robertson (2006) maintain that 
quality of life in HIV is associated with disease stage and disease symptoms. Therefore, 
proper management of symptoms may improve the quality of life of these patients 
(Breitbart & Dibiase, 2002).  
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The results of previous research on the relationship of antiretroviral treatment and quality 
of life are mixed (Cohen, Revicki, Nabulsi, Sarocco, & Jiang, 1998; Nieuwkerk et al., 
2000). Studies have shown that long-term use of highly active antiretroviral therapy 
(HAART) can control the disease, prolong survival, reduce incidence and mortality rates 
(Palella et al. 1998, Parsons et al., 2006); moderate the symptoms caused by HIV-
infection, and slow the progression of AIDS. The comprehensive study on quality of life, 
emotional status, and adherence of HIV-1- infected patients treated with efavirenz versus 
protease inhibitor-containing regimes (Fumaz et al., 2002) highlighted that quality of life 
has been found to improve with antiretroviral therapy. Moreover, significantly 
improvements in the quality of life of symptomatic HIV subjects have been noted on 
quality of life measures following antiretroviral therapy (Nieuwker et al., 2001).  
 
In a longitudinal study with a sample of 263 HIV-infected women from eight public- 
health HIV/AIDS clinics serving both rural and urban areas in the state of Georgia in the 
United States, social factors (disclosure and material resources) and psychological factors 
(fatalism, stigma, emotional distress, and intrusion) were found to be important 
determinants of quality of life in HIV (Sowell et al., 1997). In the same study, limited 
daily functioning was correlated with stigma, fatalism, employment status, and stage of 
disease. 
 
Identifying factors that diminish QoL in HIV/AIDS cases is an important step towards 
improving QoL in this population; it allows clinicians to screen for these factors, and if 
present, intervene (Holmes, Bix, Meritz, Turner & Hutelmyer, 1997). Modern studies 
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have reported differing results, particularly when determining predictors of poor quality 
of life. Among socio-demographic variables, female gender, older age, black or Hispanic 
ethnicity, lack of private health insurance, and lower education have been associated with 
lower QoL in HIV-infected persons (Bastardo, & Kimberlin, 2000), while higher income 
and employment have been associated with better QoL (Viswanathan, Anderson, & 
Thomas, 2005). In addition, previous studies have found that employed subjects living 
with HIV have significantly higher overall QoL than unemployed subjects living with 
HIV (Blalock, McDaniel, & Farber, 2002; Swindells et al., 1999). Conflicting results 
have been given in regard to gender as a socio-demographic factor that might influence 
quality of life of HIV-infected people. Some researches have documented low 
performance for women in some aspects of quality of life (QoL) (Wachtel, et al., 1992). 
Married women appeared to be more vulnerable than were men to disruptions in quality 
of life over time (Sarna et al., 1999). Some reports in literature find younger age to be 
related with better QoL (Molassiotis, et al., 2001; Sowel et al., 1997). Worse quality of 
life in the areas of physical and social functioning has been attributed to older age among 
people living with HIV/AIDS (Piette, Wachtel, Mor & Mayer, 1995). Comparisons 
between educational groups showed that those with less education reported significantly 
poorer QoL than those with more education, according to some authors (Wachtel, et al., 
1992; Lubeck & Fries, 1997). For the purpose of this study, we reviewed specific aspects 
of quality of life including physical, psychological, social relationship and environment 
in PLWHs. 
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2.4.2.1 Physical health 
The physical health domain assesses the impact of disease on the activities of daily 
living, dependence on medical substances, a lack of energy and initiative, restricted 
mobility and the capacity to work (Skevington, 2002). Physical health gives an individual 
the ability to perform and adapt to the environment. Physical health is estimated by an 
individual’s perceptions of energy and fatigue, pain and discomfort, and sleep and rest. 
The physical health domain has shown a positive relationship with overall quality of life. 
When one’s physical status was reported as high, perceptions were that physical health 
and quality of life were more positive (Sousa et al., 1999). According to Kohli, Sane, 
Kumar, Paranjape and Mehendale (2005), the HIV infection affects various domains 
associated with physical health since frequent illness and increasing fatigue affect the 
individuals’ ability to perform employment related and routine activities, and their overall 
perceptions of health. Fatigue and a CD4 T cell count less than 500 are associated with 
physical limitations and disability (Ferrando et al., 1998). Additionally, fatigue may 
affect one’s activity level and is common when using antiretroviral therapies (ARTs) 
(Bormann, Shively, Smith, & Gifford, 2001). Responses to symptoms of fatigue and pain 
often result in elimination of leisure time and physical activities (Crystal, Fleishman, 
Hays, Shapiro, & Bozzette, 2000). Previous studies of quality of life among persons with 
HIV have suggested that as the disease progresses individuals experience more symptoms 
and more problems with physical function , and role functioning (de Boer, Van Dam & 
Sprangers, 1995; Franchi & Wenzel, 1998).  
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In previous studies on quality of life of people living with HIV/AIDS, the factors found 
to have significant affect on the physical health domain were occupation and education 
(Wig et al., 2006; dos Santos et al., 2007). Skilled workers and business persons had 
better physical health domain scores as compared to others, suggesting clearly that people 
with better occupation may have better physical health. In addition, lower scores were 
seen among subjects who did not attend school or completed middle school education 
compared to those with higher education.  
 
Antiretroviral therapies taken as prescribed reduce viral loads and minimize the risk of 
drug-resistant strains of the virus (Liu et al., 2006); yet, non-adherence of ARTs ranges 
from 35% to 80% (Remien et al., 2005). Reasons for temporary discontinuation of ARTs 
include depression, poor quality of life, and ART side effects (Aversa, Kimberlin, & 
Segal, 1998). Moreover, some studies have found overall quality of life improved with 
the use of HAART (Nieuwker et al., 2000; Fumaz et al., 2002) and others observed that 
physical quality of life decreased under HAART (Gill et al., 2002). According to Liu et 
al. (2006), the decrease of physical health quality of life after HAART might be 
explained by the fact that HAART was initiated relatively early in the HIV infection. As 
in their study progressed the physical health of the men was still close to normal in early 
HIV infection, the HAART related side effects may have decreased physical health 
quality of life. Furthermore, by using HAART, many people with HIV who have been 
diagnosed with AIDS become healthy enough to return to work or school. Returning to 
work or school is often considered the benchmark of successful HIV treatment (Brooks & 
Klosinski, 1999). 
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2.4.2.2 Psychological health 
The psychological domain accesses the patient’s own thoughts about body image and 
appearance, negative feelings, positive feelings, self-esteem and person beliefs 
(Skevington, 2002). Psychological well being is the focus of intense research attention 
and is relevant to the experience of the individual (WHOQOL-HIV, 2003b). It is a 
person’s evaluative reaction to his or her life; either in terms of life satisfaction (cognitive 
evaluations) or affect (ongoing emotional reaction). Psychological well-being has been 
found to be a source of resilience against stress and becoming ill. An individual’s 
psychological well-being positively influences his/her quality of life (WHOQOL-HIV, 
2003b). HIV disease not only severely affected the physical health of the patients, but 
also disease morbidity usually results in higher deterioration of psychological domain of 
quality of life (Liu et al., 2006). As documented by the previous studies, the most 
common emotional problems reported in people living with HIV/AIDS were anger, 
irritation, depression, tension and helplessness (Kohli et al., 2005), while Chesney and 
Folkman (1994) reported shock, denial, depression, helplessness, discouragement, guilt, 
anger and fear as the main emotional problems. Psychological comorbidities, particularly 
depression, often accompany HIV infection and add to the complexity of clinical 
management. Studies from western culture have found depression to be the most 
commonly observed mental health disorder among HIV-infected subjects, affecting up to 
20% of patients (Komiti, Judd, & Grech, 2003). Depression may be associated with poor 
quality of life and shortened survival in subjects with HIV (Farinpour, Miller, & Satz, 
2003). Additionally, the comprehensive study on relationship between depression and 
quality of life in persons with HIV infection in Nigeria (Adewuya et al., 2008) showed 
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that there was the significant association between the diagnosis of depression and poorer 
quality of life. In agreement with other studies (Farinpour, Miller, & Satz, 2003; 
Sherbourne et al., 2000), found that depression is a significant predictor of quality of life 
in people with HIV infection.  
 
Highly active antiretroviral therapy (HAART) also may give hope and optimism to 
people with HIV. Researchers have found that having hope and an optimistic outlook, in 
turn, decreases their levels of depression, and even extends their life spans (Taylor, 
Kemeny, Reed, Bower, & Gruenewald, 2000). Despite these benefits, however, 
antiretroviral therapy can present significant psychological challenges to both those who 
respond well to the treatment and those who do not (Brashers et al, 1999). These can 
range from moodiness and aggressive behavior to severe depression, suicidal thoughts, 
paranoia, delusions and hallucinations. This emphasizes the need for psychological 
intervention for the affected individuals. 
 
2.4.2.3 Social relationship 
Social domain assesses personal relationships, social support and sexual activity 
(Skevington, 2002). People value their relationships with self and with others 
(WHOQOL-HIV, 2003a). Humans need to feel a sense of belonging and acceptance; they 
need to love and be loved both sexually and non-sexually. In the absence of such 
belonging, individuals become susceptible to loneliness, anxiety and depression. When 
an individual is no longer able to physically, emotionally, or sexually relate to self and 
others, quality of life is often negatively affected (WHOQOL-HIV, 2003a). Some authors 
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have suggested that earlier experiences and nowadays stigmatization may influence 
quality of life values (Watson et al., 1996). Social relationships were one of the main 
areas affected in people living with HIV/AIDS. Consequences within the social domains 
dominate; suggesting the severest impact of HIV extends across social aspect of QoL but 
also influences other important domains of health-related QoL (Sowel et al., 1997; 
Molassiotis, 2001). This is expected, as People with HIV infection often experience 
social isolation, derogation, stigmatization, discrimination and marginalization (Heckman 
et al., 1997). Stigmatization is a major stressor for individuals with HIV/AIDS (Brimbow, 
Cook, & Seaton, 2003). Brashers et al. (1999) noted that uncertainty (a chronic pervasive 
psychological distress) and stigma negatively affected adjustment and quality of life. 
Stigma influenced how individuals confronted their perception of an altered identity at 
diagnosis, lived with the illness, and dealt with the ‘‘social and physical death’’ of having 
HIV (Alonzo & Reynolds, 1995). Gray (1999) found that fear of stigma was more 
relevant to women (N = 80) living with HIV than was the fear of dying. In addition, poor 
social functioning may be associated with greater use of avoidance coping strategies such 
as withdrawal and conflictual social interactions. Social isolation and conflictual social 
interactions have been shown to interact to increase stress, resulting in poorer overall 
social functioning (Fleishman et al., 2000). 
 
2.4.2.4 Environment 
The environment does play a major role in determining health states. Environmental 
domain assesses influences of factors like financial resources, the work environment, 
accessibility to health and social care, freedom, security and participation and 
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opportunities for leisure activities on the QoL (Skevington, 2002). People would like to 
have the financial resources that they need to meet their daily needs (WHOQOL-HIV, 
2003a). Physical safety and security are important aspects of the environment because 
they give the individual emotional freedom. It is also vital to have accessibility to good 
quality health and social care that provide opportunities for acquiring new information 
and skills. The environment provides for participation in opportunities for recreation and 
leisure. A safe and secure environment promotes a high level of quality of life 
(WHOQOL-HIV, 2003b). For working individuals, employment provides not only 
financial benefits but also structure for social support, role identity and personal meaning 
(Molassiotis et al., 2001). Adults with HIV/AIDS infection often struggle with vocational 
dilemmas. Previous study on the effect of employment on quality of life and 
psychological functioning in patients with HIV/AIDS has found that those employed 
have significantly higher overall QoL than unemployed subjects (Blalock et al., 2002). In 
earlier study on the impact of HIV/AIDS on the quality of life, family support and 
occupation significantly affected the environmental domain of quality of life in HIV 
patients (Wig et al., 2006). The effect of family support on the environmental domain 
was a significant observation. Family is usually the most important component of the 
immediate environment of the patient. The family of the patient can be a major support, 
in terms of not only financial support, but also safety and security. A good and supportive 
home environment can help the patient feel better. In the same study, skilled workers and 
business persons had better scores in environment domain scores. The authors concluded 
that improving the all-round environment surrounding of HIV infected individuals will 
lead to a better quality of life. 
 
 
 
 
 36
2.4.3 Quality of life measurement 
Measurement of quality of life includes physical, functional, psychological, cognitive and 
social aspects of life which reflects the individual’s subjective perception on his current 
overall health (Lubeck & Fries, 1997). This can be carried out by using either instruments 
specifically designed for a condition or generic instruments. Tools to measure quality of 
life have also surfaced in response to the recent interest in QOL research. Researchers 
differ in their perception of the components related to QOL; therefore, tools measure 
QOL differently. 
 
The three most prominent HIV-specific quality of life instruments in the current 
circulating professional literature are (a) The Medical Outcomes Study – HIV 
(MOSHIV), (b) Multidimensional Quality of Life – HIV (MQOL-HIV), and (c) HIV 
Overview of Problems-Evaluation System (HOPES). A large body of literature 
examining the psychometrics of these tools exists (Wu et al, 1997; Revicki, Sorensen, & 
Wu, 1998; Badia et al, 2000). 
 
The MOS-HIV is a tool specific for persons living with HIV based upon a well known 
validated, pre-existing QOL tool. It will be discussed at length following. HOPES 
determines QOL based upon five summary scales including physical, psychosocial, 
medical interaction, sexual and significant others/partners domain. The HOPES was 
adapted from a QOL tool first validated on cancer patients (Schag, Ganz, Kahn, Petersen, 
& 1992). According to Ganz et al. (1993) and Schag, Ganz, Kahn, and Peterson (1992), 
the HOPES instrument has been shown to be both reliable and valid with a stable factor 
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structure. The MQOL-HIV asks 40 questions which assess mental health, physical health, 
physical functioning, financial status, partner intimacy, sexual functioning and medical 
care. Studies have determined this tool is adequately reliable, valid, and sensitive to 
changes in QOL over time (Smith et al, 1997; Herdman, Fox-Rushby, Badia et al, 2000, 
& Badia, 1997), however Badia et al. (2000) have claimed that the MOS-HIV is more 
sensitive than the MQOL-HIV when used in clinical research. While each of the 
mentioned tools has its use, the MOS-HIV is very well known secondary to its well-
known parent, the MOS tool. The MOS-HIV has demonstrated both validity and 
reliability (Franchi & Wenzel, 1997). The WHOQOL BREF was used in the current 
study because is a tool specific for persons living with HIV based upon a well known 
validated in Rwanda. 
 
2.5 RELATIONSHIP BETWEEN PERIPHERAL NEUROPATHY AND QUALITY 
OF LIFE 
Patients living with HIV/AIDS experience a wide range of symptoms associated with 
clinical manifestations of the disease, related opportunistic conditions and side-effects 
from medication (Demmer, 2001). In addition, previous studies have consistently shown 
that the presence, number, and severity of symptoms are the major determinants of 
quality of life in HIV-infected patients (Wu, 2000). The same author further stated that 
clinical stage has only a weak association with quality of life after adjusting for the 
number of symptoms.  Moreover, by interfering with their daily activities and 
relationships with the external world, peripheral nervous system diseases can greatly 
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affect the quality of life (QoL) of patients, and a worsening QoL may increase their 
disability (Cocito et al., 2006). 
 
With regards to quality of life and peripheral neuropathy in PLWHs, limited information 
is available in literature. According to the researcher only quality of life and peripheral 
diabetic neuropathy studies are available. Like all chronic pain, diabetic peripheral 
neuropathic pain (DPNP) takes a toll on patients’ quality of life. One small study found 
that quality of life was significantly (p<.01) more impaired among patients with DPNP 
than among diabetic patients without neuropathy (Benbow, Wallymahmed & Mcfarlane, 
1998). Another study of 105 patients with DPNP reported high levels of interference with 
sleep and enjoyment of life and moderate interference with mobility, employment, and 
recreational and social activity (Galer, Giana, & Jensen, 2000). Furthermore, in an earlier 
study of diabetic patients with chronic pain, pain was associated with reduction in sleep, 
walking and ability to perform domestic duties (Benbow et al., 1998).  
 
Chronic painful symptoms can have a considerable impact on an individual’s life and 
may be associated with anxiety, depression, loss of mobility and independence (Benbow 
et al., 1998). In addition, painful peripheral neuropathy has been shown to play an 
important negative role in physical and psychological functioning as well as in the overall 
quality of life of people living with HIV/AIDS (Breitbart et al., 1998). Also, Pandya et al. 
(2005) found that HIV-related neurological syndromes, including neuropathy, 
significantly reduce quality of life. Thus, increased and improved surveillance for HIV-
associated peripheral neuropathy will allow earlier interventions to improve quality of 
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life and prevent severe toxicities. Griswold et al. (2005) examined coping strategies of 
HIV patients with peripheral neuropathy and found that these strategies may differ 
according to age, gender and ethnic background in those living with HIV. 
 
2.6 SUMMARY 
This chapter has described the general overview of HIV/AIDS worldwide, including 
Rwanda. Relevant literature on peripheral neuropathy amongst and quality of life of 
people living with HIV/AIDS has been reviewed. The literature reviewed showed that 
DSPN remains one of the most common neurological complications associated with HIV 
infection or its treatment and poses enormous limitations related to functional status, 
activity levels, and physical comfort. The spectrum and the frequency of this 
complication are expected to change with continued experience and introduction of new 
antiretroviral drugs, an aging HIV-infected population, and the emergence of other long-
term complications of HIV and/or its treatment. Additionally, the assessment of QoL is 
now acknowledged as a central component of health care and healthcare research. It is 
essential that initial and ongoing assessment address symptom management to improve 
the individual’s quality of life. 
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CHAPTER THREE 
METHODOLOGY 
3.1 INTRODUCTION 
This chapter outlines the methods used in the study. It explains the rationale for the study, 
the design chosen and describes the research setting. The population, the sampling 
method, data collection and analysis are described. Finally, the ethical considerations 
regarding the study are described. 
 
3.2 RESEARCH SETTING 
This study was carried out in the Rulindo, a district located in the Northern Province, 40 
kilometers from Kigali city, in Rwanda. The Republic of Rwanda is a small, land-locked 
country in East Africa with one of the highest population densities in the world at 344 
people per square kilometer. Most recent statistics indicate a population size of 9,241,661 
(National Institute of Rwanda (NISR), 2007). In addition, the prevalence of people living 
with HIV/AIDS was estimated at 190,000, of which 160,000 were adults (UNAIDS, 
2007). According to Furth et al. (2006), Rwanda has made remarkable strides in 
antiretroviral therapy and care of opportunistic infections which occur as a result of HIV. 
By the end of September 2004, a total of 6,230 clients had started ARVs. Furthermore, 
UNAIDS/WHO/UNICEF (2007) indicated that in Rwanda, the estimated number of 
people receiving antiretroviral therapy was 34,000 in 2006. 
 
The study was based at Rutongo Hospital in Rulindo District in Rwanda. This is a 
District Hospital to which most patients from 16 Primary Health Care Centers around the 
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District are referred for HIV/AIDS services and other health services. The hospital has an 
average 100 beds and five out-patients clinic consultations per week and each PLWH 
comes twice per month. This site was chosen because it offers HIV care (Anti-retroviral 
drug, Voluntary Counseling and HIV testing, and other medical routine care). At 
Rutongo Hospital, PLWHs are sent to the ARV service provider where they are examined 
and a CD4 count is ordered.  
 
3.3 STUDY DESIGN 
A cross-sectional descriptive design using quantitative research method was used in the 
study. Thyer (2001) indicated that descriptive studies summarise the relationships 
between or among two or more variables aiming at quantifying the extent of the problem. 
A cross-sectional study involves examining the responses of different groups of 
participants at one point in time. It has the advantage of collecting information in a short 
time frame (Mertens & Mc Laughlin, 2004). Therefore; it was an appropriate study 
design, to collect data relating to the prevalence of peripheral neuropathy amongst and 
the quality of life of adults living with HIV/AIDS attending the out-patient clinic at 
Rutongo Hospital in this study at a given point in time.  
 
3.4 STUDY POPULATION AND SAMPLING 
Approximately 800 people living with HIV/AIDS have attended Rutongo hospital; more 
than 600 of these are adults. Approximately 35 adults living with HIV/AIDS attend this 
setting once a week to receive medication. The study was conducted over a 6 week 
period. A time constrained sample of 185 people living with HIV/AIDS attending this 
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setting was therefore recruited to participate in the study. Participants in this study were 
adults confirmed to have HIV/AIDS infection. The patients attending the out-patient 
clinics included those who were receiving HAART and those who needed assessment of 
their CD4 counts not receiving medication. Only those participants attending the out-
patient clinics at the time of data collection were included in the study. 
 
3.4.1 Inclusion criteria 
Only HIV-positive males and females who are: over 18 years, receiving AIDS-related 
care at Rutongo Hospital in Rulindo District in Rwanda, able to provide informed consent 
and fluent in the Kinyarwanda or English-speaking were recruited. 
 
3.4.2 Exclusion criteria 
HIV-positive patients less than 18 years of age were not included in the study. 
 
3.5 INSTRUMENTS 
Two validated instruments were used to collect data. The Subjective Peripheral 
Neuropathy Screen (SPNS) (Appendix J) was used to screen for the presence of 
peripheral neuropathy and the World Health Organization Quality of Life, short form 
(WHOQOL BREF) (Appendix L) to assess quality of life.  
 
1. Symptoms of peripheral neuropathy were measured using the Subjective Peripheral 
Neuropathy Screen (SPNS) (McArthur, 1998). This instrument is a brief self-report tool 
that was designed as a screening instrument for painful or nonpainful sensory in HIV-
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infected subjects. SPNS has six questions which cover the following symptoms: “pain, 
aching or burning”, “pins and needles” (parasthesias) and “numbness”.  Each of these six 
different symptoms was rated either as never occurring or occurring. If present at time of 
data collection, the severity of the symptoms was scored on a scale from 01 (mild) to 10 
(most severe). The symptom receiving the highest severity assessment (1-10) was 
converted into a categorical “severity grade” by means of the following raw scores are: 1 
to 3, 4 to 6 and 7 to 10 and the corresponding clinical severity grade was 1, 2, and 3 
respectively. This grade was called the subjective peripheral neuropathy grade.  
 
2. The World Health Organization Quality of Life, short form (WHOQOL BREF) was 
used in this study to determine quality of life of the participants. The WHOQOL BREF 
consists of 26 items. These items are distributed in four domains of QOL, physical health 
and level of independence with seven items, psychological well being with eight items, 
social relationship with three items, and environment with eight items. There are also two 
items that are examined separately; one for the overall quality of life and another for 
general health.  Each item uses a Likert-type five-point scale. Most scores are scaled in a 
positive direction where higher scores denote higher quality of life. Three items are not 
scaled in a positive direction but were scaled in negative direction (e.g. physical pain, 
negative feelings, dependence on medication), meaning that for these items higher scores 
do not denote higher quality of life. Participants were questioned regarding their 
experience relating the above domains in the previous two weeks. Summation and 
calculation of the mean score for each domain was calculated. Because the numbers of 
items are different for each domain as mentioned above, all domain scores were 
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calculated by taking the mean score for all items included in each domain and 
multiplying by a factor of 4. The first transformation method converts scores to range 
between 4-20, comparable with the WHOQOL-100. The second transformation method 
converts domain scores to a 0-100 scale. Where more than 20% of data is missing from a 
assessment, the assessment should be discarded. Where an item is missing, the mean of 
other items in the domain is substituted. Where more than two items are missing from the 
domain, the domain score should not be calculated (with the exception of domain 3, 
where the domain should only be calculated if < 1 item is missing).  The instrument used 
in the current study was available in Kinyarwanda version. In addition, permission to use 
this instrument was obtained from the Principal Investigator of WHOQOL BREF 
Kinyarwanda version (Hakuzimana, 2005). 
 
3 .5.1 Reliability 
The SPNS instrument was found reliable and it possesses both construct and criterion-
related validity. Using Cronbach’s alpha test the internal consistency of the SPNS was 
high (0.86) (McArthur, 1998). The WHOQOL-BREF questionnaire has been shown to 
have a good internal consistency with Cronbach’s alpha acceptable for overall quality of 
life and health satisfaction. Two week test-retest reliability shows intraclass correlation 
coefficients p for domain scores to be less than p<0.05 for all domains indicating good 
correlation between test and retest values with Cronbach’s alpha acceptable in physical 
and psychological domains (Hakuzimana, 2005). 
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3.5.2 Validity 
The test can discriminate between the symptoms of parasthesias, numbness, and lower 
extremity pain (p<0.05). In addition, it has been demonstrated that the SPNS assess 
differences in symptoms severity (p<0.05). Significant correlations were demonstrated 
for SPNS results and other tests like a neurologic examination, vibratory quantitive 
sensory testing, and severity measures. Sensitivity and specificity analysis indicates that 
numbness of the lower extremities is the symptoms reported by the SPNS that most 
correctly classifies painful sensory neuropathy. Further, the SPNS has appeared to be a 
useful tool for screening HIV-associated sensory neuropathies; it has a high specificity 
(83%) and a good positive predictive value (70%) (Venkataramana, Skolasky, Creighton, 
& McArthur, 2005). Finally, the content validity of the SPNS was established, since it 
was developed by a group of neurologists with experience and expertise in the area of 
painful sensory neuropathy. Fang et al. (2004) in their study on validation of the World 
Health Organisation quality of life instrument in patients with HIV infection concluded 
that the WHOQOL-BREF would be a useful tool in assessing quality of life in patients 
with HIV infection. 
 
3.5.3 Translation 
The Subjective Peripheral neuropathy screen (SPNS) (Appendix K) was translated from 
English to Kinyarwanda by a professional translator. In order to ascertain if the translated 
version into Kinyarwanda relay to the intended meaning in the English version, two other 
translators assisted back translation of this instrument to the English. The back translated 
version was the same as the original English version with no changes needed 
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3.6 PILOT STUDY 
The aim of the pilot study was to identify how well respondents understood the questions 
and how long it took to answer the questions.  Ten patients with HIV/AIDS who satisfied 
the inclusion criteria at Rutongo Hospital were interviewed for the pilot study after 
written consent was obtained from them. These patients were not included in the main 
study. Balnaves & Caputi (2001) indicated that performing a pilot study assists in the 
identification of problems and benefits associated with the questionnaire design. The 
necessary changes to the instrument were made after piloting. For example, the question 
requesting for how long has the participant known he/she is HIV positive, was changed 
into how many years has the participant known he/she is HIV positive. The time it took 
for respondents to complete the questionnaire was between twelve and fifteen minutes. 
 
3.7 PROCEDURE  
After obtaining the ethical clearance from the University of the Western Cape’s Senate 
Research Committee, ethical approval was sought from the Minister of state in charge of 
HIV/AIDS and other epidemics in the Ministry of Health (APPENDIX B). In addition, 
permission to conduct the study was obtained from the Director of Rutongo Hospital. 
One physiotherapist and one counselor were recruited as research assistants; they were 
explained their role in the study, the aim and the nature of the study, as well as all ethical 
issues. The sample consisted of patients who were attending the Rutongo Hospital for 
out-patient services. The patients were approached and invited to partake in the study 
while waiting to be attended to by the doctors, where the aims and objectives of the study 
were explained. All subjects who volunteered to participate provided written informed 
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consent. The researcher completed SPNS and WHOQOL-BREF. Demographic data 
including age, gender, level of education, occupation, marital status and the length of 
time participants known their-HIV status was also collected from the participants. 
 
3.8 DATA ANALYSIS 
Responses to the questionnaires were entered and analysed in the Statistical Package for 
the Social Sciences (SPSS) for Window Version software 15.0. Descriptive statistics (i.e. 
means, standard deviations, frequencies and percent) were used to examine demographic 
characteristics of the sample, prevalence of peripheral neuropathy and WHOQOL BREF 
domain scores. One-way Analysis of variance and Independent sample T-tests were 
performed to determine a significant difference between quality of life domain scores and 
demographic characteristics. Chi-square Tests were used to demonstrate association 
between demographic characteristics and severity of peripheral neuropathy. 
 
3.9 ETHICAL CONSIDERATION 
The researcher obtained permission to conduct the study from the Higher Degrees 
Committee of the University of the Western Cape and ethical permission from the 
Research and Study Grant Committee of the University of the Western Cape. Secondly, 
permission was sought from the Minister of state in charge of HIV/AIDS and other 
epidemics in the Ministry of Health in Rwanda. The researcher obtained permission from 
the Director of Rutongo Hospital. The researcher explained the aim and objectives of the 
study to participants prior to their participation. Written consent was sought from the 
participants and they were informed of the voluntary nature of the study and their right to 
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withdraw from the study at any time if they so wished. In addition, participants were 
assured of respect, confidentiality and anonymity. For those who reported PN, advice 
such as avoiding walking long distances, standing for long periods of time, or wearing 
restrictive shoes was given to them. The results of the study will be availed to the director 
of Rutongo, the head of ARV service and to those interested participants. 
 
3.10 SUMMARY 
This chapter described the methodology used in this study. It explained the research 
setting and the whole procedure of how the data was collected and analysed. Finally, the 
chapter explained how ethical considerations were applied in this study. The findings of 
the study are presented in the next chapter. 
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CHAPTER FOUR 
RESULTS 
4.1 INTRODUCTION 
In this chapter the results of the study are described. The results are described under 
various headings which reflect the general picture of the prevalence of peripheral 
neuropathy symptoms among adults living with HIV/AIDS attending the out-patient 
clinic at Rutongo Hospital in Rulindo District in Rwanda, by giving types, area and 
severity of symptoms. The quality of life of adults living with HIV/AIDS in Rulindo 
District is also presented. 
 
4.2 DEMOGRAPHIC CHARACTERISTICS OF THE STUDY SAMPLE 
A total of 185 participants completed the two questionnaires from December 2007 to 
January 2008. The participants’ mean age was 38.70, with a standard deviation of 9.538. 
The ages ranged from 19 years to 73 years. The majority of the sample fell into the age 
range of 31-40 years. The study sample consisted of more female131 (70.8 %) than males 
54 (29.2%). In the present sample, the majority of the participants 160 (86.5%) were farm 
workers, while 3 (1.6 %) were self-employed. Approximately half of the participants 94 
(50.8%) were married while the remaining part did not have a partner as they were single 
or widowed. Only three of the participants had university education, whereas most 
participants had a primary level of education. The majority of participants 110 (59.5%) 
had known their HIV-positive status for a period of 2 to 4 years. Table 4.1 below 
illustrates these results. 
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Table 4.1: Demographic characteristics of the study sample (n=185) 
Demographic 
variables 
Characteristics Frequency Percentage 
Age Less than 30 35 18.9 
31-40 79 42.7 
41-50 49 26.5 
51-60 16 8.6 
More than 60 6 3.2 
Gender Female 131 70.8 
Male 154 29.2 
Occupation Farm workers 160 86.5 
Unemployed 12 6.5 
Public or private 
employed 
10 5.4 
Self employed 3 1.6 
Marital status Married 94 50.8 
Widowed 53 28.6 
Separated 24 13.0 
Single 12 6.5 
Cohabiting 2 1.1 
Level of education Primary 112 60.5 
Secondary 15 8.1 
University 3 1.6 
Not at all 55 29.3 
Time elapsed since 
HIV diagnosis 
< 2 years 54 29.2 
2 to 4 110 59.5 
5 to 7 12 6.5 
8 to 10 7 3.8 
> 10 years 2 1 
 
 
4.3 PERIPHERAL NEUROPATHY  
This section includes the prevalence and type of peripheral neuropathy symptoms as well 
as severity of those symptoms. 
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4.3.1 Prevalence of peripheral neuropathy symptoms  
A total of 185 adults living with HIV/AIDS attending out-patient clinic at Rutongo 
Hospital received and completed the Subjective Peripheral Neuropathy Screen (SPNS) 
(Appendix A). Peripheral neuropathy was defined as being present if an individual 
described responses on both the presence and severity of each of three types of symptoms 
(“pain, aching, or burning”; “pins and needles”; and “numbness”). The overall prevalence 
of peripheral neuropathy in the sample of people living with HIV/AIDS attending out-
patient clinic at Rutongo Hospital was 75 (40.5%). Figure 4.1 illustrates the overall 
prevalence of peripheral neuropathy symptoms of the participants. 
 
59.5%
40.5%
Yes
No
 
Figure 4.1: Overall prevalence of Peripheral neuropathy symptoms (n=185) 
 
4.3.2 Type and area of peripheral neuropathy  
Three types of symptoms “pain, aching or burning”, “pins and needles” (parasthesias) 
and “numbness” were assessed. Each of these three types of symptoms was assessed in 
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terms of two body locations such as hands or arms versus feet or legs. Thus, six different 
symptoms depending on type and location were assessed. The most common reported 
symptoms were pain, aching or burning while the least common reported symptoms were 
pins and needles in feet and legs. The symptoms reported in this study showed that the 
upper extremities were more commonly affected than lower extremities (Figure 4.2).  
76
56
61.3
56
45.3
49.3
0
10
20
30
40
50
60
70
80
Pain,aching, or burning Pins and needles Numbness
Types of symptoms
%
 o
f s
ym
pt
om
s
Hands,arm
Feet, legs
 
Figure 4.2 Types of peripheral neuropathy symptoms for PLWHs (n=75) 
 
4.3.3 Severity of symptoms 
The severity of the symptoms is determined by calculating the Subjective Peripheral 
Neuropathy Grade. The Subjective Peripheral Neuropathy Grade is determined by using 
the symptom with highest score between 1 and 10. These were then categorised into three 
groups. A Subjective Peripheral Neuropathy Grade of 1 illustrated a mild peripheral 
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neuropathy, 2 moderate and 3 severe. A symptom scored between 1 and 3 equal a clinical 
grade of 1, 4 and 6 a clinical grade of 2 then 7 to 10 a clinical grade of 3. 
 
In the present study, Subjective Peripheral Neuropathy mean was 1.69, with a standard 
deviation of 0.885. Figure 4.3 below shows that out of 75 participants who reported 
symptoms at the time of data collection, 44 (58.7 %) were in grade 1 whereas 10 (13.3 %) 
were in grade 2 and 21 (28 %) in grade 3. This study found that they were 21 male and 54 
female living with HIV/AIDS with peripheral neuropathy. 
 
Chi-square test was conducted to analyse the difference between the genders of the 
participants living with HIV/AIDS with peripheral neuropathy in relation to Subjective 
Peripheral Neuropathy Grade.  There was no significant difference in the severity of PN 
between males and females (χ2=0.909, P=0.635).  
 
Figure 4.3: Distribution of participants according to the Subjective Peripheral 
Neuropathy Grade. (n=75) 
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Fig 4.4 illustrates Subjective Peripheral Neuropathy Grade by age. The majority of 
patients reported symptoms at the time of data collection fell into the age range of 31-40 
years, followed by the age range of 41-50 years; while few patients fell in age group of 
more than 60 years. Chi-square Tests were used to demonstrate association between age 
and Clinical Severity Grade. There was a significant association (p=0.000< 0.005).  
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Fig 4.4: Representation according to age group versus Subjective Peripheral 
Neuropathy Grade (n=75) 
 
4.4 QUALITY OF LIFE  
This section includes the mean quality of life scores, demographic information and mean 
scores of quality of life domains and their respective mean differences. 
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4.4.1 Mean quality of life domain scores 
The mean score in four domains of quality of life was the highest for the psychological 
domain followed by the social domain, physical health domain and environmental. Figure 
4.5 illustrates the mean quality of life scores. 
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Figure 4.5: Quality of life domain scores 
 
4.4.2 Quality of life according to different demographic characteristics 
Table 4.3 shows demographic information and mean scores of quality of life domains and 
their respective mean differences. Multiple comparisons of means were performed using 
Tukey’s test. The results from the Student’s t-test and one-way analysis of variance 
(ANOVA) showed that a significant difference was observed with respect to the ages of 
the participants in the psychological domains (P=0.028). Lower scores were seen among 
subjects who were older than 60 years compared to those who were less than 30 years 
old. However, there was no significant difference of quality of life in the physical, social 
and environmental domains amongst the different age groups. The comparison of the 
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mean raw scores of quality of life in men and women showed that there is a statistically 
significant difference in the social relationships domains (P=0.033) with lower scores for 
women in this domain. In the present study, there was no significant difference between 
quality of life and occupation.  
 
One way analysis of variance (ANOVA) was also performed to determine if there was a 
significant difference between scores of the different domain and marital status. There 
were no statistically significant differences between quality of life domains according to 
the marital status. In the social relationships domain, there was however a statistically 
significant difference (P=0.030) for the subjects who were cohabiting when compared to 
those who were widowed with subjects who were cohabiting having better scores. 
Comparisons of mean scores of quality of life revealed significant differences in the 
physical health (P=0.000), psychological (P=0.000), social relationships (0.033) and 
environment domains (0.040) and level of education; scores were lower for those who did 
not attend school compared to those with primary, secondary and tertiary level of 
education. The mean scores were lower in the physical domain for who did not attend 
school. The variable relating to time since HIV diagnosis indicated that subjects who 
knew their HIV status for two to four years had higher mean scores in the social 
relationships domain when compared to those knew about their status for less than two 
years.   
 
Table 4.2 Relationship between quality of life scores and demographic 
characteristics (n=185).   
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Demographic 
characteristics 
Mean quality of life scores 
Physical 
health 
Psychological 
health 
Social 
relationships 
Environment 
Age     
 < than 30 
years 
13.06 15.17* 13.60 12.51 
31-40 13.04 14.90 13.58 12.57 
41-50 12.31 14.92 13.49 12.59 
51-60 12.44 14.00 12.00 12.44 
> than 60 
years 
10.83 12.83* 12.50 13.17 
Gender     
 Male 12.59 14.74 13.91* 12.52 
Female 12.78 14.84 13.18 * 12.60 
Occupation     
 Public or  
private 
employed 
12.90 15.10 14.00 12.70 
Self-
employed 
13.00 15.00 15.00 13.33 
Unemployed 12.17 14.42 13.92 11.58 
Farming or 
livestock 
12.75 14.82 13.28 12.63 
Marital status     
 Married 12.57 14.81 13.46 12.50 
Single 13.25 14.58 13.08 12.08 
Separated 12.46 14.21 12.29 12.54 
Cohabiting 12.50 16.00 14.00 * 12.00 
Widowed 13.00 15.09 13.81 * 12.85 
Education     
 Not at all 11.60 * 13.87 * 12.71 * 12.09 * 
Primary 12.93 * 15.13 * 13.62 * 12.82 * 
 Secondary 13.21 15.60 14.07 12.40 
 University 14.00 16.00 14.00 13.00 
Time elapsed 
since HIV 
diagnosis 
    
 < 2 years 12.70 14.48 12.78 * 12.26 
2 to 4 12.69 14.96 13.78 * 12.67 
5 to 7 13.58 15.50 13.67 13.08 
8 to 10 12.29 114.14 12.43 12.57 
> 10 years 11.50 13.50 10.00 12.50 
*P< 0.05 
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4.4.3 Distribution of the population studied according to the presence and absence 
of peripheral neuropathy symptoms and quality of life scores  
Independent samples T-Test was performed to determine if significant differences existed 
between quality of life domain (physical, psychological, social and environmental) of 
participants with and without peripheral neuropathy symptoms. Quality of life in PLWHs 
with peripheral neuropathy showed significantly lower scores in the physical (p=0.013) 
and psychological (p=0.020) domains.  There was no statistically significant difference 
between the two groups with regards to the social and environmental domains. The 
quality of life domain scores have been summarized in Figure 4.6. 
 
12.35
13.2
14.4
12.2
12.75
13.515.113.1
0
2
4
6
8
10
12
14
16
Physical Psychological Social Environmental
QOL domains
M
ea
n 
Q
O
L 
sc
or
es
PLWHs with PN
PLWHs without PN
 
Figure 4.6 QoL domain scores between participants with and without peripheral 
neuropathy symptoms (PLWHs with PN, n=75; PLWHs without PN, n=110). 
 
One way analysis of variance was performed for finding out significance between quality 
of life domain scores and subjective peripheral neuropathy grade. The physical, 
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psychological and social domain scores showed significant differences in participants 
with grade 1 and grade 3 scores in participants with peripheral neuropathy; lower scores 
were seen among subjects with grade 3 scores when compared to those with grade 1 
scores. The description of one way Analysis of variance (ANOVA) between quality of 
life domain scores and clinical severity grade is detailed in Table 4.3. 
Table 4.3 Quality of life domain scores and subjective peripheral neuropathy grade 
(n=75) 
Domains for QOL Grade 1 Grade 2 Grade 3 P value 
Physical 12.93* 11.30 11.14* 0.006 
Psychological 14.98* 14.50 13.19* 0.004 
Social relationship 13.68* 13.90 11.95* 0.008 
Environmental 12.64 12.20 11.30 0.284 
*P< 0.05 
 
4.6 SUMMARY 
This chapter highlighted the findings of the study. The results showed that the 31 to 40 
years old age group had a high prevalence of people living with HIV/AIDS with 
peripheral neuropathy symptoms, while the mean score of quality of life domains was 
lowest for environmental domain, followed closely with physical health domain. The 
study identified also contributing factors for quality of life in PLWHs. The discussion of 
these results will be presented in chapter five. 
 
 
 
 
 
 
 
 
 60
CHAPTER FIVE 
DISCUSSION 
5.1 INTRODUCTION 
The aim of the study was to determine the prevalence of peripheral neuropathy amongst 
and the quality of life of adults PLWHs attending the out-patient clinics at Rutongo 
Hospital in Rwanda. In this chapter, the significant findings of the study will be 
discussed. The limitations of the study are also highlighted. 
 
5.2 DEMOGRAPHIC STATUS OF PLWHs 
In this study, the majority of the participants were female (70.8%). These results are 
similar to those of Jelsma, Maclean, Hughes, Tinise and Darder (2005). The 
predominance of women is due to more women attending clinic as in 2007, 46 % only of 
people living with HIV/AIDS (15.4 million) were women worldwide (UNAIDS 2007). 
According to Calderon (1997), biological, socio-economic and cultural factors make 
women more vulnerable to HIV infection. The same author stated that women are 
affected by gender imbalance; they do not have equal opportunities to education, on-
going training and jobs as men and tend to be excluded from the formal economy. It was 
further indicated that HIV infection was six times more prevalent in women than in men 
(Population Council Epidemiology, 2002).  Thus, the high prevalence of women 
participation in the current study could be explained by the fact that at the time of data 
collection women were the most participants attending Rutongo hospital.  
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The findings of this study revealed that the majority of the sample fell into the age range 
of 31-40 years. This proportion indicates that the prevalence of HIV could be high among 
youths and young adults in the population studied. This is not surprising because people 
in this age range tend to be more sexually active, hence causing them to be at high risk of 
HIV infection. The similar age range was found in a previous study conducted in Nigeria 
on relationship between depression and quality of life in persons with HIV infection 
(Adewuya et al., 2008). 
 
The present study showed that approximately half of the participants (50.8%) attending 
the out-patients clinics at Rutongo hospital were married. A similar result was found in 
previous study on perceived psychosocial needs, social support and quality of life in 
subjects with HIV/AIDS (John, Ndebbio, & Udoma, 2003). Additionally the current 
study found a high percentage (28.6%) of widowed people compared to an earlier study 
conducted in Zambia on quality of life of men and women living with HIV/AIDS, where 
the percentage of widowed was 9% (Mweemba, 2008). This might be related to the 1994 
Rwandan genocide and marital separation due to HIV. In addition, the reason explaining 
this occurrence is because of the high mortality rate among PLWHs. Their males may be 
dying due to AIDS. 
 
5.3 PERIPHERAL NEUROPATHY  
The diagnosis of peripheral neuropathy can generally be made by a healthcare provider 
who is experienced in the treatment of HIV disease based on a history of the symptoms 
and a comprehensive physical examination which includes testing of the reflexes and 
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evaluation of the sense of vibration, touch, pressure, and pain in the extremities (Swanson 
et al., 1998). Different prevalence rates of peripheral neuropathy in people living with 
HIV/AIDS have been reported in the literature. This may be due to different methodology 
of studies, defining criteria, and patient populations.  
 
In the present study, the diagnosis of peripheral neuropathy was established by a 
researcher based on the subjects’ responses from subjective peripheral neuropathy screen 
(SPNS). Pain, parasthesias, and numbness were the three symptoms that differentiated 
those with peripheral neuropathy from those without. 
  
Using the subjective peripheral neuropathy screen (SPNS) the overall prevalence of 
peripheral neuropathy in the sampled participants of the study was 75(40.5%) out 185 
adults PLWHs attending out-patients clinic at Rutongo Hospital. This result was similar 
to findings in studies conducted internationally and in Africa. Mbuya et al. (1996) found 
peripheral neuropathy rates in Kenya to be 15 (37.5%) out of PLWHs; Skopelitis et al. 
(2006) found peripheral neuropathy rates in United Kingdom (UK) to be 36 (36%) out 
100 PLWHs, Smyth et al. (2007) found 42% in Melbourne; Parry at al. (1997) found 44% 
in Zimbabwe, Schifitto et al. (2002) found 135 (36%) of 375 in Etats-Unis. The lowest 
prevalence 329 (13.1%) of 2515 PLWHs was reported in a previous study conducted in 
Etats-Unis on modification of the incidence of drug-associated symmetrical peripheral 
neuropathy by host and disease factors in the HIV outpatients study (Lichtenstein et al., 
2005). This study was aimed at identifying factors associated with the clinical diagnosis 
of symmetrical peripheral neuropathy during the era of highly active antiretroviral 
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therapy. These conflicting figures compared to the findings of this study are due to 
differences in the minimum criteria for making a diagnosis, sample size and exclusion 
criteria. As documented recently, clinical tools aimed at measuring peripheral neuropathy 
in HIV/AIDS have been developed (Cherry et al., 2005; McArthur, 1998; Venkataramana 
et al., 2005). 
 
According to the findings of the present study, 41.3% of participants with peripheral 
neuropathy were in the age group of 31-40 years. This is in disagreement with a study 
that has found increasing age as a predictor of developing peripheral neuropathy (Lopez 
et al., 2004). Peripheral neuropathy is a recognized side effect of certain antiretroviral 
therapy and can be caused by advanced HIV disease (Nicholas et al., 2007). The present 
study did not assess the clinical stages of the HIV infection and under which ARV drugs 
participants were subjected. Therefore the factors that could influence the presence of 
peripheral neuropathy were not known.   
 
Individuals with HIV/AIDS experiencing DSPN may present with a number of different 
complaints. The earliest symptoms of peripheral neuropathy are pain, numbness, and 
tingling in the hands and feet in the classic "sock and glove" distribution (Delakas, 2001; 
Simpson & Cikurel, 2006). The results of this study showed that the most symptoms were 
pain, aching or burning, followed by numbness while the least symptoms were pins and 
needles. These results are comparable to the findings of McArthur (1998) and Nicholas et 
al. (2002) studies indicating that these symptoms acceptably identified most people with 
peripheral neuropathy in HIV/AIDS. A contradictory result was found in a previous study 
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(Konchalard, Wangphonpattanasiri, 2007) where numbness was the dominant symptom 
in all patterns of HIV-related neuropathy. Harrison and McArthur (1995) have suggested, 
the pain and parasthesias could be early phenomena, which as the neuropathy “burns” 
out, leave numbness as the more prominent symptom. 
 
Severity of peripheral neuropathy in people living with HIV/AIDS can range from mild 
discomfort to a debilitating condition, robbing a person of the ability to walk or even to 
stand (Herrmann et al., 2001; Schifitto et al., 2002). In addition, many people with early 
or mild peripheral neuropathy do not experience any symptoms and, again, the worst 
symptoms generally occur in people with more advanced immunosuppression (lower 
CD4 cell counts) (Simpson & Cikurel, 2006). Participants in this study were adults 
confirmed to have HIV/AIDS infection and receiving HAART. The presence of PN in 
this sample can result from the direct infection of neurons with human immunodeficiency 
virus (HIV), opportunistic infection of neurons because of generalized 
immunosuppression, or from highly active antiretroviral therapy (HAART) (Hurst, 1999; 
Moyle and Sadler, 1998).  
 
The study indicated that the majority of people living with HIV/AIDS with peripheral 
neuropathy were in grade 1 compared to grade 2 and grade 3. This indicates that 
peripheral neuropathy was mild in the majority of people living HIV/AIDS attending out-
patients clinics at Rutongo Hospital. This may indicate that the physical health domain of 
quality of life of those subjects was affected moderately in terms of ability to walk, work, 
and participate in activities of daily living. Previous studies of quality of life among 
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persons with HIV have suggested that as the disease progresses, individuals experience 
more symptoms and more problems with physical function, and role functioning (de 
Boer, Van Dam & Sprangers, 1995; Franchi & Wenzel, 1998). The physical discomfort 
and pain resulting from these symptoms may make it difficult to conduct basic daily 
activities.  In addition, among HIV-positive patients, disease progression is related to 
decreasing energy and increasing difficulties with daily activities and pain (Sousa et al., 
1999). 
 
5.4 QUALITY OF LIFE OF PLWHs 
Living with HIV/AIDS remains a severe strain for those afflicted, due to a variety of 
reasons. These include physical and psychological effects of HIV-related symptoms, 
toxicity of HAART, the hardship of having to adhere to a rigid medication regimen, 
implications of the HIV-infection for the patient’s relationships and sex life, 
stigmatization and the fear of dying from the illness (Pierret, 2000). This section 
discusses specific aspects of QoL including physical, psychological, social relationship, 
environment and contributing factors for the QoL in PLWHs.  
 
5.4.1 Physical health domain 
The physical health domain assesses the impact of the disease on the activities of daily 
living, dependence on medical substances, a lack of energy and initiative, restricted 
mobility and the capacity to work (Skevington, 2002). In the present study, the mean 
score fell in intermediate level (12.72) in the physical domain of QoL. As noted in the 
literature, research has shown that nearly one third of PLWHIV reported problems with 
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mobility, limitation of usual activity and pain or discomfort (Hughes et al., 2004). These 
problems might also have contributed to the large number of subjects who rated lower 
scores in the physical domain of WHOQOL BREF in the present study.  
 
As acknowledged by previous studies physical health quality of life deteriorated with 
HIV progression (Burgess et al., 1993; Liu et al., 2006), while the side effects of HAART 
may cause as much physical discomfort as the symptoms of the illness including 
peripheral neuropathy, nausea, vomiting, anemia, headache, skin rashes, neutropenia, 
diarrhea, and abdominal discomfort (Maenza & Flexner, 1998).  
 
Moreover, the factors found to have significant affect on the physical health domain was 
the level of education. In the present study lower scores were seen among subjects who 
did not attend school compared to those with primary education in the present study. 
These results support the findings by Dos Santos et al. (2007) where lower scores were 
seen among subjects who did not attend school or completed middle school education 
compared to those with higher education. Furthermore, the results of this study observed 
no significant difference between quality of life domains and different occupations of the 
respondents. This could have been caused by the homogeneity of the sample regarding 
occupation where 86.5% of participants were farm workers.  In contrast, Wig et al. 
(2006) reported that skilled workers and business persons had better physical health 
domain scores as compared to others.  
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5.4.2 Psychological health domain 
The psychological domain accesses the patient’s own thoughts about body image and 
appearance, negative feelings, positive feelings, self-esteem and person beliefs 
(Skevington, 2002). In addition, after being diagnosed, people confronted with their HIV-
positive status are highly stressed and uncertain, despite the availability of HAART 
(Flowers, Duncan & Knussen, 2003) and their lives may be devastated by the need to 
deal with the new medical, personal and social situation (Green & Smith, 2004). In the 
current study the participants had quality of life scores in psychological domain close to 
the high level (between 15 and 20). This demonstrates that the majority of people living 
with HIV/AIDS were in the acceptance stage. According to Murphy and Melby (1999), 
during the acceptance stage people begin to take considerable control over their lives 
exercising self-determination and autonomy. Needs identified during this stage relate to 
the need for accurate information, education and knowledge. These results support the 
results found by Uwimana (2005), where most of the participants in Rwanda had received 
psychosocial support. This suggests that psychological needs were met to a certain extent. 
This might also indicate that there is a good service for meeting psychological needs of 
patients with the HIV disease.  
 
This study further found that the level of education significantly affected the 
psychological domain of QoL. The observation of significant difference in the 
psychological domain in relation to the educational level of more than high school 
possibly suggests better coping attitudes towards disease. Contrary, in this study, beyond 
having some education, level did not seem to make any difference. According to 
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Ichikawa and Natpratan (2004) as the education of the patients increases, the better their 
psychological domains scores. It reflects that education enhances problem solving and 
active decision making and helps the patient to cope with the dread of the disease better, 
both emotionally and problem focused (Chesney & Folkman, 1999).  
 
Furthermore, a significant difference was observed with respect to the ages of the 
participants in the psychological domains (P=0.028). Subjects who were less than 30 
years had better scores in the psychological domain. This could indicate that young 
PLWHs are likely to cope with the disease better. Nonetheless, age has been associated 
with quality of life in a previous study (Piette, Wachtel, Mor, & Mayer, 1995), worse 
quality of life in the areas of physical and social functioning has been attributed to older 
age among people living with HIV/AIDS. These findings are similar to those among 
Zambian men and women with HIV/AIDS that showed younger persons reported more 
positive feelings, better cognitive functioning, higher self-esteem, more satisfaction with 
physical appearance and body image, and generally more satisfaction within the 
psychological domain of quality of life then older persons, confirming some reports in the 
literature (Mweemba, 2008). Additionally, young people are often diagnosed in an early 
stage of disease while older individuals are more likely to be diagnosed once 
experiencing later stages of HIV infection. 
 
5.4.3 The social domain 
Social domain assesses personal relationships, social support and sexual activity 
(Skevington, 2002). The mean score fell in intermediate level (13.39) in the social 
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relationships domain of QoL in this study, indicating that patients’ social contacts and 
sexual activity were affected obviously to a reasonable extent.  This trend seems 
consistent with the stigmatization of HIV/AIDS in the society. Research indicates that 
people still hold stigmatization attitudes towards those living with HIV and AIDS 
(PLWHs) confirms this expectation (Herek, Capitano, & Widaman, 2002).   
 
The factors found to have significant affect on the social domain, were gender and 
marital status. The presence of significant association on the social domain in this study 
is in contrast with an earlier study which assessed the impact of HIV/AIDS on the quality 
of life (Wig et al., 2006), where there was a lack of any significant association on the 
social domain in relation to demographic variables. 
 
Comparison of mean raw scores of quality of life in men and women showed a 
statistically significant difference in the social relationships domains with lower scores 
for women. This is in agreement with a previous study where women with HIV/AIDS 
had lower quality of life scores as opposed to men despite having less advanced disease 
(Nirmal, Divya, Dorairaj & Venkateswaran, 2008). Women with HIV/AIDS live longer 
and are likely to face a chronic disabling condition that is progressive (Hader, Smith, 
Moore, & Holmberg, 2001).  Additionally, women often face more severe discrimination 
than men if they are known to be HIV-positive, they are more likely to sacrifice their own 
health for the welfare of their family and postpone treatment or because they have low 
income or perhaps they drop out of schools early. This can lead to physical abuse and the 
loss of economic stability if their partners leave them. Moreover, the latter can reflect 
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stigma and discrimination associated to difficulties to disclose their HIV status in social 
settings (work, family, and friends) and for comfortable sex life. Furthermore, as the 
number of women with HIV disease increases, and with no cure in immediate sight, 
understanding how HIV positive women adapt psychologically and socially has acquired 
a new importance (Nannis, Patterson, & Semple, 1997). The same authors stated that the 
psychosocial response of women to HIV infection might have implications for disease 
progression and quality of life.  
 
Cohabiting subjects had better social domain scores compared to divorced subjects in the 
present study; this suggests that divorced people living with HIV/AIDS are less able to 
actively engage in social activities such as visiting with friends or close relatives and less 
able to perform work-related tasks in job, home, and educational settings. According to 
Mweemba (2008), marital status influences quality of life; subjects who are married or in 
relationships, reported a higher level of quality of life for the social relationships domain. 
Those in relationships may enjoy better social support. Moreover, a number of HIV-
infected individuals are in long-term relationships with HIV-infected individuals, from 
whom they may derive additional stability and support. Those in a long-term relationship 
also need only disclose their serostatus to one person, their partner, thus alleviating some 
of the anxiety felt while revealing HIV-positive status. 
 
The variable time elapsed since HIV diagnosis indicated that subjects who knew their 
HIV status for two to four years, had mean higher scores than those who knew it less than 
two years in the social relationships domain in the present study. In contrast, Sakthong, 
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Schommer, Gross, Sakulbumrungsil and Prasithsirkal (2007) found that patients who had 
been diagnosed with HIV infection for a long time were more likely to have lower 
psychological domain. Although, the other domains of quality of life were not 
significantly associated with years since HIV diagnosis in the present study, meaning that 
there was no difference in domain scores in relation to the duration of disease. This 
indicates that subjects who knew their HIV status for two to four years may have been 
living with the illness longer and therefore may have had more time to develop adaptive 
coping strategies, or they may have had more experience with and more time to adjust to 
their medication regimes, which may have resulted in them feeling better. Based on the 
findings of this study, this suggests that the development of strategies to increase the self-
esteem of HIV positive individuals and support them to protect their own health by 
avoiding new sexual transmissible infection is the most important, in order to meet the 
particular needs and concerns of new infected in immediately time following an HIV 
diagnosis. 
 
5.4.4 Environmental domain 
Environmental domain assesses influences of factors like financial resources, the work 
environment, accessibility to health and social care, freedom, security and participation 
and opportunities for leisure activities on the QoL. In this study the environmental 
domain had the minimum QoL score (12.57) of the four QoL domains. The number of 
items that contributed to the deterioration of the environmental domain includes the lack 
of information regarding a number of issues like protective measures for transmission of 
the HIV infection, the progression of the disease and ARV therapy. Lack of money to 
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meet the needs and transportation were indentified as other contributory factors. Similar 
results were obtained in a previous study that assessed the impact of HIV/AIDS on 
quality of life (Wig et al., 2006). 
 
The findings were not surprising as the research setting was situated in rural areas. 
Additionally, the road network and communication facilities of the rural hospitals are 
poor. These factors have contributed to the fact that only a few health facilities have 
adequate trained personnel to distribute antiretroviral therapy to HIV positive persons. 
The long distances to health centers and lack of transport have contributed to people 
seeking health care late, usually when they have advanced HIV disease (Phalazde et al., 
2005). 
 
The level of education significantly affected the environmental domain of QoL in 
PLWHs in this study. Lower scores were seen among subjects who did not attend schools 
compared to those with primary, secondary and university education. These results 
confirm the findings of previous studies (Holmes et al., 1997; Eriksson, et al., 2000), 
where the level of education was associated with quality of life of PLWHs. These 
findings support those reported by O'Connell, Skevington and Saxena, (2003) who found 
a large difference for the environment domain by education level. 
 
In earlier study on the impact of HIV/AIDS on the quality of life, family support and 
occupation significantly affected the environmental domain of quality of life in PLWHs 
(Wig et al., 2006). The same authors stated that the effect of family support on the 
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environmental domain was a significant observation. They further urged that family is 
usually the most important component of the immediate environment of the patient. Also 
the family of the patient can be a major support, in terms of not only financial support, 
but also safety and security while a good and supportive home environment can help a 
patient feel better. In the same study, skilled workers and business persons had better 
scores in environment domain scores. Therefore, improving the all round environment 
surrounding of HIV infected individuals, will lead to a better quality of life. 
 
5.5 LIMITATIONS OF STUDY 
There are a number of limitations to this study: 
• No medical investigations or assessment tools for identifying peripheral neuropathy 
were used. Therefore, peripheral neuropathy and quality of life were based on self-report.  
• In the present study, the critical indicators of disease progression, such as CD4 count 
and viral load, were not assessed. Thus conclusions could not be made as to the 
relationship between the progression of the HIV infection and peripheral neuropathy as 
well as quality of life.  
• This study is limited by being a cross-sectional assessment, which limits contributory 
assumptions about the ways in which peripheral neuropathy might affect physical health, 
psychological and social relationship domains of adults PLWHs at Rutongo Hospital. 
• The study population was not a random sample of people living with HIV/AIDS in 
Rulindo District. The participants were those who were actively seeking routine medical 
care. Those who did not schedule or keep regular clinic visits were not included and 
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consequently, the results of this study might not be generalized to all HIV patients in 
Rulindo District. 
 
5.6 SUMMARY 
The discussion dealt with the major findings of the study. Similarities with other studies 
were found with regard to the prevalence of peripheral neuropathy and quality of life of 
people living with HIV/AIDS. The summary of the study, conclusion and 
recommendations based on the findings will be explained in the next chapter. 
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CHAPTER SIX 
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS  
6.1 SUMMARY 
The aim of the study was to determine the prevalence of peripheral neuropathy amongst 
and the quality of life of adults living with HIV/AIDS in Rulindo District in Rwanda.  
 
Out of 185 adult people living with HIV/AIDS who have completed the subjective 
peripheral neuropathy screen (SPNS) at Rutongo hospital, 75 (40.5%) reported at least 
one of the six symptoms of peripheral neuropathy. Out of 75 (40.5%) participants who 
reported symptoms at the time of data collection, 44 (58.7%) were in grade 1 whereas 10 
(13.3%) were in grade 2 and 21 (28%) in grade 3. While they had quality of life scores in 
the physical health, psychological, social relationship and environmental domains fell in 
intermediate level (between 10 and 14.9). The mean score of domains was highest for the 
psychological health (14.81), followed by social domain (13.39), then physical domain 
(12.72), and lowest for environmental domain (12.57). Additionally, this study found that 
education significantly affected physical health domain scores. Age and education 
influence psychological domain scores. Gender, marital status, education and time 
elapsed since HIV diagnosis significantly affected social domain. The level of education 
significantly affected the environmental domain of quality of life. The findings suggest 
that the assessment of both peripheral neuropathy and quality of life be included in the 
intervention programmes designed for people living with HIV/Aids. 
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6.2 CONCLUSION 
 A total of 75 (40.5 %) out 185 adults PLWHs attending out-patients clinic at Rutongo 
Hospital in Rulindo District in Rwanda experienced peripheral neuropathy in varying 
grades.  These findings confirm that peripheral neuropathy remains a prevalent problem 
among PLWHs. Those PLWHs who are experiencing peripheral neuropathy symptoms 
should work closely with their medical providers to find the combination of medical 
treatment and supportive therapies that works best for them.  Additionally, the assessment 
of QoL is now acknowledged as a central component of health care and healthcare 
research. In the present study, PLWHs had quality of life scores in the physical health, 
psychological, social relationship and environmental domains which fell in intermediate 
level; physical and environment domains are the ones which are most impaired in people 
living with HIV/AIDS attending out-patient clinic at Rutongo Hospital. With regard to 
the environmental domain, it is impossible to know how much of the environmental 
problems experienced are due to HIV or due to living in an impoverished area, a 
comparison with WHOQOL Bref scores for the general population would have been very 
useful. The study findings also demonstrate that socio-demographic characteristics such 
as age, education, marital status and gender influence quality of life of adults PLWHS. 
Therefore, the results could allow health care providers to screen these factors so that 
they can intervene to improve quality of life and better care. 
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6.3 SIGNIFICANCE OF THE STUDY 
The results from this study will contribute to the knowledge of the prevalence and 
severity of peripheral neuropathy among adults living with HIV/AIDS and its 
relationship on quality of life. In addition, the results could be used in Rwanda by health 
care providers to design programmes that manage the peripheral neuropathy that could 
negatively affect the quality of life of adults living with HIV/AIDS.  Physiotherapists 
should be encouraged to screen PLHWs who are referred to them using a basic tool such 
as the SPNS. If necessary they would then be able to include the treatment of peripheral 
neuropathy when managing these patients.  
 
6.4 RECOMMENDATIONS 
Based on the results of the study, the following recommendations for managing 
peripheral neuropathy and for improving quality of life were made: 
 
• The prevalence of peripheral neuropathy was high in adults PLWHs attending out-
patients clinic at Rutongo hospital. Healthcare providers should assess for this common 
problem so that appropriate intervention and follow up can be offered to patients as this 
condition can impair functional ability and limit physical activity.  
• Future studies are warranted with regard to the impact of improved peripheral 
management on people living with HIV/AIDS and their quality of life. 
• While quality of life may change in the fullness of time, a longitudinal study could 
demonstrate better the relationships between effects of the disease progression and 
impact of PN on quality of life domains.  
 
 
 
 
 78
• Furthermore, it is essential that initial and ongoing assessment address symptom 
management to improve the individual’s quality of life. 
• Thus, future research should attempt to address gender issues in relation to quality of 
life of HIV- infected individuals as identification of gender issues may assist in the 
design of gender -specific interventions to improve quality of life. 
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A. POPULATION CHARACTERISTICS 
 
 
A.1 Gender 1. Male 1 
2.Female 2 
 
 
A.2 How old are you? Age completed in years  
 
 
A.3 What is your employment 
status? 
1.Employed 1 
2.Self employed 2 
3.Student 3 
4.Unemployment 4 
5. Farmer 5 
 
 
A.4 What is your marital status? 1.Married 1 
2.Single 2 
3.Divorced 3 
4.Cohabiting 4 
5.Widowed 5 
 
 
 
A.5 What is your level of Education? 1. Not at all 1 
2. Primary 2 
3. Secondary 3 
4.University 4 
 
 
 
A.6 For how long have you known 
you are HIV positive? 
Time completed in years  
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B. SUBJECTIVE PERIPHERAL NEUROPATHY SCREEN (SPNS) 
 
1. INSTRUCTION FOR RECORDING SUBJECTIVE PATIENT-ELICITED 
SYMPTOMS: 
 
Ask the patient to rate the severity of each symptom (a-f) on a scale of 01 (mild)-10 
(most severe). Enter the severe score for each symptom in the column marked 
Presence/Severity. 
 
If symptom has been present in the past, but not since the last visit, enter “00”/ Currently 
Absent. If the symptom has never been present, enter “11”/Always Been normal. 
 
Always 
Been 
normal 
Currently
Absent 
Mild……………………………………………………….Severe
11 00 01 02 03 04 05 06 07 08 09 10 
 
Symptom(s)        Presence/Severity 
 
a. Pain, aching, or burning in hands, arms: 
    
b. Pain, aching, or burning in feet, legs:                                                
 
c. “Pins and needles” in hands, arms:                                                    
 
d. “Pins and needles” in feet, legs:                                                       
 
e.Numbness (lack of feeling) in hands, arms:                                                                
 
 f. Numbness (lack of feeling) in feet, legs:                                          
 
 
 
2. INSTRUCTION FOR GRADING SUBJECTIVE PATIENT-ELICITED 
SYMPTOMS: 
 
Use highest severity score recorded in (a-f) above to obtain a subjective peripheral 
neuropathy grade: 
 
Presence/Severity score of: 01-03     = Grade of 1 
                                            04-06     = Grade of 2 
                                            07-10     = Grade of 3 
                                           11 or 00 =   Grade of 00 
 
1. Subjective peripheral neuropathy grade?.................. 
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C. WHOQOL-BREF 
 
 
After reading each question, assess your feelings, and circle the number on the scale 
for each question that gives the best answer. 
 
  Very 
poor 
Poor Neither poor 
nor good 
Good Very good 
1(G1) How would your rate your 
QOL? 
1 2 3 4 5 
 
 
  Very 
dissatisfied 
Dissatisfied Neither 
satisfied nor 
dissatisfied 
Satisfied Very 
satisfied 
2(G4) How satisfied 
are you with 
your life? 
1 2 3 4 5 
 
 
The following questions ask about how much you have experienced certain things in 
the last two weeks. 
  Not at 
all 
A little moderate 
amount 
Very 
much 
An 
extreme 
amount 
3(F1.4) To what extent do you 
feel that physical pain 
prevents you from doing 
what you need to do? 
1 2 3 4 5 
4(F11.3) How much do you need 
any medical treatment to 
function in your daily 
life? 
1 2 3 4 5 
5(F4.1) How much do you enjoy 
life? 
1 2 3 4 5 
6(F24.2) To what extent do you 
feel your life to be 
meaningful? 
1 2 3 4 5 
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  Not at 
all 
A 
little 
 moderate Very 
much 
Extremely
7(F5.3) How well are you able to 
concentrate? 
1 2 3 4 5 
8(F16.1) How safe do you feel in 
your daily life? 
1 2 3 4 5 
9(F22.1) How healthy is your 
physical environment? 
1 2 3 4 5 
 
The following questions ask about how completely you experience or were able to do 
certain things in the last 2 weeks 
  Not at 
all 
A 
little 
Moderately 
amount 
Mostly Completely 
10(F2.1) Do you have enough 
energy for everyday 
life? 
1 2 3 4 5 
11(F7.1) Are you able to accept 
your bodily 
appearance? 
1 2 3 4 5 
12(F18.1) Have enough money to 
meet your needs? 
1 2 3 4 5 
13(F20.1) How available to you is 
information that you 
need in your day-to –
day life? 
1 2 3 4 5 
14(F21.1) To what extent do you 
have opportunity for 
leisure activities? 
1 2 3 4 5 
 
 
  Very 
poor 
Poor Neither 
poor nor 
good 
Good Very 
good 
15(F9.1) How were you able to get 
around? 
1 2 3 4 5 
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The following questions ask you to say how good or satisfied you have felt about 
various aspects of your life over the last two weeks. 
  Very 
dissatisfied
Dissatisfied Neither 
satisfied 
nor 
dissatisfied 
Satisfied Very 
satisfied
16(F3.3) How satisfied are you 
with your sleep? 
1 2 3 4 5 
17(F10.3) How satisfied are you 
with your ability to 
perform your daily 
activities? 
1 2 3 4 5 
18(F12.4) How satisfied are you 
with your capacity for 
work? 
1 2 3 4 5 
19(F6.3) How satisfied are you 
with yourself? 
1 2 3 4 5 
20(13.3) How satisfied are you 
with your personal 
relationships? 
1 2 3 4 5 
21(F15.3) How satisfied are you 
with your sex life? 
1 2 3 4 5 
22(F14.4) How satisfied are you 
with the support you 
get from your 
friends? 
1 2 3 4 5 
23(F17.3) How satisfied with the 
conditions of your 
living place? 
1 2 3 4 5 
24(F19.3) How satisfied are you 
with your access to 
health services? 
1 2 3 4 5 
25(F23.3) How satisfied are you 
with your transport? 
1 2 3 4 5 
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The following question refers to how often you have felt or experienced certain 
things in the last two weeks. 
 
  Never Seldom Quite 
often 
Very 
often 
Always 
26(F8.1) How often do you have 
negative feelings such as 
blue mood, despair, 
anxiety, depression? 
1 2 3 4 5 
 
 
 
THANK YOU FOR YOUR HELP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
